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SUMMARY
Heart failure (HF) is the leading cause of hospitalization and hospital readmission for
patients aged over 65 and older in the United States, with roughly one in five individuals
hospitalized with heart failure being readmitted within 30 days of discharge. HF affects
6.2 million Americans with health care costs of almost $31 billion per year. Management
of HF is a complicated process that requires frequent clinic visits and outpatient manage-
ment systems for hemodynamic monitoring and patient-reported symptoms. Hemodynam-
ically guided HF management via tracking pulmonary congestion and taking proactive care
have shown efficacy in reducing HF-related readmission significantly. However, the cost-
prohibitive nature of such pulmonary congestion monitoring systems precludes their usage
in the large patient population affected by HF. For that reason, an inexpensive alternative
is necessary to bring hemodynamic monitoring systems to the large patient population af-
fected by HF, not only in the United States but also around the world.
Advancement of novel biomedical sensor technologies and advanced signal processing
and machine learning algorithms have merit in tracking health parameters unobtrusively.
A promising sensing modality is seismocardiography (SCG), defined as the measurement
of local chest wall vibrations associated with the cardiac cycle. SCG has shown efficacy in
tracking changes in cardiac contractility via the cardiac timing intervals it yields, such as the
pre-ejection period (PEP). However, different sensing modalities of SCG acquisition exist
using accelerometer and gyroscope based sensors, and inter-subject variability of these
acquired signals has made it challenging to develop a robust hemodynamic monitoring
system using SCG. Accordingly, most researches in the field of SCG focus on advancing
the understanding and processing of the signal in healthy individuals. The translation of
the SCG-based hemodynamic monitoring approaches into the actual patient population, for
example, in patients with HF, is necessary to validate such a system for both inpatient and
outpatient HF management.
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This work addresses some of these key aspects. First, the two sensing techniques for
acquiring SCG, accelerometer and gyroscope sensors, are compared in their ability to track
cardiac contractility changes via PEP estimation. Second, general time, frequency, and am-
plitude features are extracted from the SCG signals and used in a population level machine
learning regression algorithm to estimate key cardiovascular features for healthy subjects
and patients with HF, by overcoming the inter-subject variability of the signals. Third, the
SCG sensing system, along with the signal processing and machine learning algorithm,
is verified and validated with two gold-standard clinical procedures: cardiopulmonary ex-
ercise test (CPX) and right heart catheterization (RHC). Gas exchange variables from the
CPX and changes in pulmonary congestion from the RHC procedures were estimated using
features from simultaneously recorded SCG signals to demonstrate the efficacy of such a
sensing system and algorithm to track relevant hemodynamic parameters in patients with
HF.
The algorithms and methods presented in this work can enable remote cardiovascular
health monitoring for patients with HF to enable personalized titration of care, and im-
proving medication adherence in a hemodynamically-guided HF management system. The
inexpensive wearable sensing technology has the potential to be a viable and ubiquitous
alternative to the already-proven hemodynamic congestion monitoring systems, which can
improve the quality of life and outcome in patients with HF by reducing hospitalization and




1.1 Motivation and Background
As an outcome of improved health care systems and lower mortality rates, life expectancy
is growing rapidly worldwide. The aging population (aged 65 or older) is projected to
grow from an estimated 524 million in 2010 to nearly 1.5 billion in 2050, with most of
the increase in developing countries [1]. This growing aging population needs frequent
and longitudinal health care for various diseases such as cardiovascular diseases (CVDs),
respiratory complications, cancers, and neurological disorders. CVDs, including heart fail-
ure (HF), are consistently ranked as the number one cause of death in the United States
(US) and contribute to approximately 6 million deaths per year [2] with an annual cost of
$30.7 billion, mainly due to hospitalization costs [3]. The difficulty of HF management is
attributed not only to a high rate of HF-related admissions—approximately 1 million per
year in the US [4]—but also as the leading cause of hospital readmission for patients aged
65 and older [5]. It is projected that the total direct medical costs due to HF with all CVDs
will increase from $396 billion in 2012 to $918 billion in 2030 [6].
Due to the high 30-day readmission rate and associated health care cost related to HF,
the Hospital Readmissions Reduction Program (HRRP), under the Affordable Care Act
(ACA) passed in March 2010, identified HF among the three targeted conditions (acute
myocardial infarction and pneumonia being the other two) to reduce hospitalization. The
HRRP program sought to penalize hospitals with higher rates of readmission for these three
targeted conditions to reduce unnecessary hospital costs [5]. While this policy may have
led to a reduction in HF 30-day readmissions (readmissions for HF declined from 23.5%
in 2008 to 21.4% in 2014) [7, 8], much of that reduction may have been due to adminis-
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trative re-classification or upcoding of patients [8]. In addition, early independent studies
suggest that penalizing hospitals for higher 30-day HF readmissions led to an increase in
30-day, 90-day, and 1-year risk-adjusted HF mortality [9]. Finally, two large randomized
trials, one with only HF patients and the other with medically and socially complex pa-
tients with a history of hospitalization, failed to demonstrate the utility of care transition
programs to decrease hospital admissions [10, 11]. For this reason, the health care systems
and cardiologists are exploring novel implanted or wearable technologies to assist in HF
management in addition to hospital readmission reduction penalties and hospital-to-home
care transitions [12].
HF management is a unique and critical task that requires frequent hospital visits and
recurrent monitoring from clinicians. However, frequent monitoring by clinicians is not
enough to mitigate the impact of HF. For this reason, clinicians are exploring implantable
and non-invasive biosensors to monitor these affected patient populations both in hospi-
tal and at home [13, 12]. Clinicians have explored different outpatient home monitoring
techniques for patients with HF that include daily weight monitoring and telemonitoring
of patient-reported symptoms [11, 14], implantable bioimpedance monitors [15, 16], non-
invasive bioimpedance monitors [17], natriuretic peptides [18], implantable hemodynamic
sensors [19, 20, 21], and non-invasive lung fluid congestion monitoring [22]. Unfortu-
nately, except for the direct measurement of intracardiac filling pressures and non-invasive
lung fluid congestion monitoring, no other approaches for outpatient HF monitoring has
successfully shown improvement in outcomes for patients with HF in large randomized
controlled trials [13, 23, 15, 22].
An implantable pressure sensor, CardioMEMS (CardioMEMS HF System, Abott, Chicago,
IL, USA), was one of the first hemodynamic monitoring systems for tracking the pulmonary
artery pressure and volume status in HF patients, and has shown efficacy in reducing HF-
related rehospitalization by 30% [24] and was approved by the FDA in 2014. CardioMEMS
has shown the importance of tracking filling pressure (via tracking changes in pulmonary
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congestion) of the heart as an early predictor of the progression of compensated hemody-
namically stable HF patient to a symptomatic acute decompensated HF patient, as shown
in Fig. 1.1. For that reason, by sensing the increased filling pressure of the heart, the clini-
cians can have more time to titrate the necessary set of medications to reduce the underlying
congestion and alternate the course of decompensation in affected the individuals.
Figure 1.1: Progression of Heart Failure Pathophysiology. Adapted from [25]
Another pulmonary congestion monitoring system that has shown efficacy in HF man-
agement is the Remote Dielectric Sensing Technology (ReDS, Sensible Medical Innova-
tions Ltd.; Netanya, Israel), a non-invasive technology that uses a wearable vest with tis-
sue dielectric measurement capabilities to quantify lung fluid concentration [22]. Similar
to CardioMEMS, ReDS technology aims to identify worsening pulmonary vascular con-
gestion prior to the development of overt clinical symptoms. It uses the differences and
ratios of dielectric coefficients in pulmonary tissue (i.e., the ratio of fluid to air) to cre-
ate a sensitive and direct indicator of fluid concentration in the lungs [26]. A study of 50
patients showed that ReDS-guided HF management may reduce readmissions for patients
discharged after acute decompensated HF [22]. The results of a larger randomized study
of 268 patients were presented in 2019 and showed that ReDS-guided HF management
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prevented 48% of HF readmissions [27]. Furthermore, there are current studies under-
way to examine whether ReDS technology can guide inpatient decision-making regarding
readiness for the discharge of HF patients [28].
Although both CardioMEMS and ReDS systems have shown efficacy in reducing HF-
related readmission, the high-cost associated with each technology (> $25,000 for Car-
dioMEMS and $43,000 for ReDS) make them financially infeasible solutions of HF man-
agement for the large population affected with HF, both in the US and around the world.
Thus, the development of inexpensive cardiovascular health monitoring devices, which can
track hemodynamic parameters effectively in the hospital and at home, can help in HF
management, improve the quality of life of the affected individuals and potentially reduce
the costs of care. Fig. 1.2 illustrates a wearable sensor ecosystem that can enable remote
cardiovascular health monitoring system for patients with HF.
Figure 1.2: Concept of a wearable cardiovascular health monitoring system to enable re-
mote longitudinal monitoring of patients with cardiovascular and respiratory diseases, and
cancer survivors by: (1) recording wearable signals during daily life activities and exercise,
(2) processing the signals and estimate relevant physiological variables and (3) enabling
physicians/caregiver to intervene based on the longitudinal assessment of cardiovascular
health.
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1.2 Specific Aims and Contributions
The ultimate goal of this work is to develop and validate a wearable sensor to monitor car-
diovascular health for patients with HF by (1) investigating different modalities of wearable
sensing systems to track changes in hemodynamics with physiological and pharmacolog-
ical perturbation, (2) developing robust signal processing and machine learning algorithm
to extract clinically relevant features from these wearable signals by overcoming the inter-
subject variability of the signals, and (3) validating the wearable sensor and algorithms to
track clinical parameters in patients with HF against gold-standard clinical procedures. To
achieve these goals in a systematic way, the work has three specific aims:
1. To analyze the performance of different wearable sensors and robust population-
level regression model in estimating changes in cardiac contractility via pre-ejection
period (PEP) estimation.
2. To estimate exercise capacity and exercise intolerance using a wearable sensor in
patients with HF to stratify risks associated with HF.
3. To track changes in intracardiac and pulmonary pressures with pharmacological per-
turbation using a wearable sensor in patients with HF to track hemodynamics non-
invasively.
1.3 Thesis Organization
Chapter 2 and 3 provide the scientific background of the work while Chapters 4-6 present
original research. Finally, Chapter 7 presents the conclusions and future direction of
the work. Specifically, Chapter 2 provides the physiological background of the cardio-
pulmonary system and the pathophysiological changes of the heart with HF. Chapter 3
provides a brief overview of different wearable sensing systems to monitor cardiovascular
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health. Chapter 4-6 are organized in order of the specific aims of the work mentioned




2.1 Anatomy of the Heart
The heart is located in the middle of the chest, slightly to the left of the sternum, and it
has four chambers and four valves, as shown in Fig. 2.1. The two upper chambers are the
two atria, and the two lower chambers are the two ventricles. Out of the four valves, two
are atrioventricular (AV), and two are semilunar (pulmonary and aortic) valves. The valve
between the right atrium and right ventricle is the tricuspid valve, and the valve between
the right ventricle and pulmonary artery is the pulmonary valve. The valve between the left
atrium and left ventricle is the mitral valve, and the valve between the left ventricle and
aorta is the aortic valve.
Figure 2.1: Anatomy of the heart with black arrows showing the blood flow.
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The heart pumps blood to different organs of the body through an intricate network
of arteries, capillaries, and veins, known as the cardiovascular system. It is connected
to the lungs through the pulmonary artery and veins, known collectively as the pulmonary
circulation. The right side of the heart (right atrium and right ventricle) receives blood from
the venae cavae (the largest veins of the body) and sends the blood to the lungs. The blood
returns back to the left side of the heart (left atrium and left ventricle) and flows to other
parts of the body except for the lungs. The circulation from the left side of the heart flows
to the whole body and its return back to the right side is known as the systemic circulation.
Fig. 2.2 shows the systemic and pulmonary circulation of the blood. The blood with low
O2 concentration and high CO2 concentration returns back to the right atrium of the heart
through the superior and inferior venae cavae, which goes through the right ventricle to
the lungs through the pulmonary artery. The blood receives oxygen from the alveoli in the
lungs and returns back to the left atrium through pulmonary veins. It travels through the
mitral valve to the left ventricle, and when the left ventricle contracts, it pumps out through
the aortic valve to the aorta and the other organs of the body.
2.2 Cardiac Cycles and Cardiac Timing Intervals
The cardiac cycle of the heart is broadly divided into two phases: diastole, the filling phase,
and systole, the ejection phase. Diastole and systole may be subdivided into four phases:
1) Isovolumetric relaxation, 2) Ventricular filling (further subdivided into two sub-phases:
passive and active filling), 3) Isovolumetric contraction, and 4) Ventricular Ejection. The
cardiac cycle is depicted in Fig. 2.3.
The cardiac cycle begins with the isovolumetric relaxation (diastole) phase when both
the ventricles are relaxed, and both the AV and semilunar valves are closed. During the
second phase of ventricular filling, blood starts to flow from the atria to the ventricles
passively since the pressure in the ventricles is lower than the ventricles. This early phase
of ventricular filling is also known as the rapid filling/inflow phase. As the ventricles are
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Figure 2.2: Systemic and pulmonary circulation of blood, with white arrows showing the
direction of blood flow.
filling, the pressure in the ventricles increases and the flow of the blood decreases, which
is known as diastasis. At the end of the ventricular filling phase, the atria contracts and the
remaining blood flows to the ventricles, which is known as atrial systole or atrial “kick”.
At the end of this ventricular filling phase, the AV valves close, and the heart enters into the
isovolumetric contraction (IVC) phase. In the IVC phase, the ventricles start to contract.
The pressure increases to match the pressure of the aorta/pulmonary artery. When it reaches
the pressure, the semilunar valves open, and blood flows to the aorta and pulmonary artery
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Figure 2.3: The cycle diagram depicts one heartbeat of the continuously repeating cardiac
cycle, namely: ventricular diastole followed by ventricular systole, etc.—while coordinat-
ing with atrial systole followed by atrial diastole, etc. The cycle also correlates to key
electrocardiogram tracings: the P wave (atrial systole), the QRS complex (ventricular sys-
tole), and the T wave (which indicates ventricular diastole);—all shown as color red.
from the left and right ventricles, respectively. As the blood ejects from the ventricles, the
pressure decreases. When it decreases below the pressure in the aorta/pulmonary artery, the
semilunar valves close and the heart enters into the isovolumetric relaxation phase again.
Isovolumetric relaxation and ventricular filling comprise the “Diastole” period, whereas
IVC and ventricular ejection comprise the “systole” period of the cardiac cycle.
The IVC time period is an important indicator of cardiac contractility, and is also known
as the pre-ejection period (PEP) [29, 30]. Multiple studies have shown that PEP is inversely
correlated with cardiac contractility [29, 30, 31]. The time for the left ventricular ejection
is another important metric for left ventricular health, and the ratio of PEP and the left
ventricular ejection time (LVET) (PEP/LVET) is also shown to be inversely correlated with
cardiac contractility [32].
Other important cardiovascular parameters include stroke volume (SV), cardiac output
(CO), and ejection fraction (EF). SV is the volume of blood that the heart pumps out in
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each heartbeat. It is measured as the difference between the end-diastolic volume (EDV)
and the end-systolic volume (ESV). CO is the average volumetric flow rate of blood from
the heart in liters per minute, and is calculated by multiplying SV with heart rate (HR).
EF is the measurement of the fraction of blood the heart pumps in each heartbeat, and is
calculated as the ratio of SV over EDV. The equations to calculate the parameters are given
below as well.
SV = EDV − ESV (2.1)





2.3 Heart Failure Pathophysiology
HF is a syndrome caused by structural or functional abnormalities of the heart, which re-
sult in impairmed myocardial contractility (systolic dysfunction) or impairmed ventricular
filling (diastolic dysfunction) that lead to reduced CO and elevated intracardiac pressure
[33, 7]. HF is often characterized by symptoms such as dyspnea, edema and fatigue [34]
and signs such as elevated left ventricular filling pressure and peripheral edema [35, 36].
Fig. 2.4 shows a pictorial demonstration of the two cases of HF in contrast to a healthy
heart.
2.3.1 Systolic Heart Failure
In the case of systolic HF, the heart muscle becomes weak and enlarged. It cannot pump
enough oxygen-rich blood forward to the rest of the body when the ventricles contract. In
systolic heart failure, the EF is lower than normal (<45%). This can cause blood to back up
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Figure 2.4: Comparison of systolic and diastolic heart failure with a normal healthy heart.
Adapted from [37].
into the lungs and cause shortness of breath and eventually ankle swelling (edema). This
phenotype of HF is commonly referred to as HF with reduced ejection fraction (HFrEF).
2.3.2 Diastolic Heart Failure
In the case of diastolic HF, the heart muscle becomes stiff (low compliance). It does not
relax normally between contractions, which keeps the ventricles from filling with blood.
EF is often in the normal range (>45%), but preload is diminished thus leading to reduced
CO. This can still lead to the backup of blood into the body and affect the organs such as




WEARABLE CARDIOVASCULAR HEALTH MONITORING
Advancement of sensing systems, digital technologies, and advanced data processing tech-
nologies have shown an increase in the wearable health care monitoring systems to monitor
the health of an individual both for self-health tracking (fitness/activity monitoring) and
for medical level monitoring for relevant patient populations (hemodynamic monitoring)
by monitoring vital signs[38]. These vital signs include heart rate, respiration rate, body
temperature, blood pressure, blood glucose, and oxygen saturation. Wearable sensors for
measuring these parameters comprise various shapes and form factors, including smart-
watches, wearable chest patches, chest belts, earworn sensors, finger clip sensors, wrist
bands, and instrumented vests. [38]. To monitor these vital signs for both healthy individ-
uals and patients with various diseases, myriad sensing modalities have been explored and
researched, including electrocardiogram, impedance cardiogram, seismocardiogram, bal-
listocardiogram, photoplethysmogram, and galvanic skin response. [39, 38]. Out of these
different sensing modalities, some can record the central cardiovascular parameters (elec-
trical and mechanical activity of the heart), and some can record the peripheral parameters
related mainly to the vasculature or sympathetic activity (vasoconstriction, vasodilation,
and skin conductance). Table. 3.1 and Fig. 3.1 (a) illustrate representative signals that can
measure central hemodynamic parameters of the cardiovascular system noninvasively. The
following sections will explain these sensing modalities briefly and discuss their usability
in remote HF management.
3.1 Electrocardiogram
The electrocardiogram (ECG) signal captures the propagation of action potentials in the
heart. The ECG can be measured as the potential difference between various points on
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Table 3.1: Noninvasive Biosignals for Monitoring Central Hemodynamic / Electrophysio-
logic Parameters Indicative of Cardiovascular Health.
Signals Aspect Unit Obtrusive/Portable
Electrocardiogram Measures electrical activity











Seismocardiogram Measures local chest vi-
bration associated with the
movement of the heart and
pumping of blood through
the vasculature
mg No/Yes
Ballistocardiogram Measures the forces acting
on the body associated with
movement of blood through
the vascular tree
N No/ Maybe
the body with skin-mounted electrodes. By different configurations of these electrodes, the
ECG projection at different directions can be measured [40]. The ECG shown in Fig. 3.1(a)
is recorded in a Lead II configuration as demonstrated in Fig. 3.1(b).
The characteristic feature points depict the depolarization (starting of contraction of the
heart muscles) and repolarization (starting of relaxation of the heart muscles) of the heart
muscle, as also explained in Fig. . The P wave represents the start of depolarization of the
atria (atrial systole/kick), the QRS complex represents the depolarization of the ventricles
(ventricular systole) with q-wave as the start of the ventricular systolic phase, and the T
wave represents the repolarization of the ventricles.
The ECG has been used to monitor the rhythm of the heart and for detecting abnor-
mal rhythm or abnormalities in the heartbeats (or shape of the signals or peaks), which are
known as arrhythmias, and ST-segment elevation for myocardial infarction (heart attack).
In the hospitals, the clinicians generally use a 12-lead ECG system as an early diagnos-
tic tool [40]. ECG can be measured using a Holter-type ambulatory monitor or patch, a
modality that is very common for arrhythmia detection in outpatient monitoring [41, 42].
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Figure 3.1: (a) Representative wearable signals with characteristic feature points. (b) Typ-
ical sensor placements for ECG, ICG, SCG and BCG with the red arrow and +/- sign
showing the lead II configuration for the ECG.
3.2 Impedance Cardiogram
The impedance cardiogram (ICG) signal captures the electrical conductivity (impedance)
of the thorax that changes with the pulsatile flow of the blood ejected from the heart with
each heartbeat [43]. The ICG sensing system consists of four pairs of electrodes, as shown
in Fig. 3.1(b), two pairs on the neck, and two pairs near the diaphragm, The outer pair of
electrodes are current electrodes, and the inner pair of electrodes are voltage electrodes.
An electrical current is passed between the current electrodes, and the potential difference
between the voltage electrodes is measured, and the thoracic impedance is estimated using
Ohm’s law [44].
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The ICG is used to measure several hemodynamic parameters and cardiac timing in-
tervals, such as SV, cardiac output CO, PEP, and LVET [44]. As shown in Fig. 3.1(a),
the B and X points represent the aortic valve opening (AO) and aortic valve closing (AC)
respectively [45]. The B-point is defined as the inflection point of the waveform, or point
of maximum second-derivative; the X-point is defined as the minimum point of the signal
following the global maximum. The ICG has been often used as a reference standard for
AO and AC estimation due to its convenience compared to echocardiography, an imaging
modality to view the heart in a noninvasive way. However, recent studies have shown that
ICG derived PEP (time difference between the Q or R peak of the ECG and the B-point of
the simultaneously recorded ICG) overestimates the PEP extracted from echocardiography
[46, 45, 47].
3.3 Seismocardiogram
The seismocardiogram (SCG) signal is the local vibration of the chest wall due to heartbeat,
and it was first discovered and characterized by Bozhenko [48], and first applied clinically
by Salerno and Zanetti, using an accelerometer placed on the mid sternum [49]. In 1994,
Crow used concurrently recorded echocardiogram images to identify fiducial points in the
SCG waveform corresponding to CTIs [50]. As research in this field grew, researchers
delved more deeply into the correlation between specific SCG features and events seen on
echocardiography [51, 52]. Such studies showing the correlation between SCG features
and known CTIs provide the most concrete basis for the use of SCG to monitor cardiac
function. For the last decade, the SCG signal has been studied extensively where ampli-
tudes and timing intervals of different peaks of the SCG signal have been used to derive
cardiovascular parameters in daily life activities [53] and to detect various diseases [54, 55,
56].
The majority of the research on SCG signals [39, 57, 58] focuses on the linear acceler-
ation of the chest wall in the dorso-ventral axis, with the underlying assumption that chest
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vibrations due to the heartbeat are mainly comprised of linear motion. However, a recent
study by Migeotte, et al. has shown that the rotational component represents more than
60% of the total kinetic energy transferred from the heart to the body in both healthy sub-
ject, and persons with CVDs [59]. This study suggests that the rotational component of
chest wall vibrations may provide more information regarding the mechanical aspects of
the heart, in addition to the linear component. Recently Tadi, et al. used a gyroscope on the
mid sternum to record the mechanical activity of the heart [60]. They found that time inter-
vals between the ECG R-wave and some peaks within the gyroscope signal correlated well
with AO and AC, measured using echocardiography. Fig. 3.1(a) shows two typical SCG
signals from the accelerometer (SCGACC) and gyroscope (SCGGYRO) sensor, where the AO
and AC complexes are marked. Researchers typically use the specific peaks in these AO
and AC complexes to obtain CTIs from SCG with the help of concurrently recorded ECG
R-peak as a reference [39, 58, 51].
Recent studies have demonstrated the utility of SCG in monitoring cardiovascular health
for persons with CVDs [39, 23, 58, 61, 55, 62]. As SCG can be recorded using an unobtru-
sive portable sensor placed on the chest wall [39, 58], it has shown promise in monitoring
cardiovascular health during exercise and daily life activities and has the potential in remote
home management for patients with HF.
3.4 Ballistocardiogram
The ballistocardiogram (BCG) signal is a measurement of the recoil forces of the body in
reaction to the cardiac ejection of blood into the vasculature [63], which was first observed
by Gordon in 1877 [64]. The BCG is generally recorded in the longitudinal (head-to-foot)
direction [39] using a modified weighing scale [65], bed or table-based systems [63] and
modified toilet seats [66]. The bottom picture of Fig. 3.1(a) shows the longitudinal BCG
recorded using a modified weighing scale [65].
Researchers have been used the characteristic features points in the BCG signal to track
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hemodynamics in healthy subjects [67, 68] and patients with CVDs [69]. Researchers have
shown the changes in intervals between simultaneously recorded ECG R-peak and BCG I
and J peak (R-I and R-J intervals) are correlated with cardiac contractility (PEP) [67, 70].
Aydemir, et al. has shown that the features of a modified weighing scale based BCG signal
can be used to assess the clinical state of patients with HF [71]. Another recent study has
shown the application of bed-based BCG in detecting sleep stages [72].
Though BCG has proven its merits in monitoring cardiovascular health both in healthy
subjects and patients with CVDs, it can be corrupted by motion artifacts, its morphology
can be affected by gravity, and any contact of the body with external objects can affect the
repeatability of the measurement [39]; it has been proved that the ideal environment for as-
sessing the BCG would be in microgravity [73, 74, 75]. These limitations may preclude the
usage of BCG in cardiovascular health monitoring when a person is moving or exercising.
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CHAPTER 4
PERFORMANCE ANALYSIS OF GYROSCOPE AND ACCELEROMETER
SENSORS FOR WEARABLE SEISMOCARDIOGRAPHY
4.1 Overview
Systolic time intervals such as the pre-ejection period (PEP) are important parameters for
assessing cardiac contractility that can be measured non-invasively using seismocardiogra-
phy (SCG). Recent studies have shown that specific points on accelerometer and gyroscope
based SCG signals can be used for PEP estimation. However, the complex morphology and
inter-subject variation of the SCG signal can make this assumption very challenging and
increase the root mean squared error (RMSE) when these techniques are used to develop a
global model. In this study, we compared gyroscope and accelerometer based SCG signals,
individually and in combination, for estimating PEP to show the efficacy of these sensors
in capturing valuable information regarding cardiovascular health. We extracted general
time domain features from all the axes of these sensors and developed global models using
various regression techniques. In single axis comparison of gyroscope and accelerometer,
angular velocity signal around head to foot axis from the gyroscope provided the lowest
RMSE of 12.63±0.49 ms across all subjects. The best estimate of PEP, with a RMSE of
11.46±0.32 ms across all subjects, was achieved by combining features from the gyro-
scope and accelerometer. Our global model showed 30% lower RMSE when compared to
algorithms used in recent literature. Gyroscopes can provide better PEP estimation com-
pared to accelerometers located on the mid sternum. Global PEP estimation models can be
improved by combining general time domain features from both sensors. This work can
be used to develop low cost wearable heart monitoring device and to generate a universal
estimation model for systolic time intervals using single or multiple sensor fusion.
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4.2 Introduction
The pre-ejection period (PEP) of the heart is defined as the time elapsed from the start of
ventricular depolarization to the ensuing opening of the aortic valve, and is an important
parameter for assessing cardiac health outside of clinical settings [30, 29, 31]. In particular,
the changes in PEP resulting from exercise stressors can provide insight into the ability of
the heart to respond appropriately to increased sympathetic nervous system activity and
increased demand for blood flow to the muscles. An important recent finding was that the
clinical status of patients with heart failure (HF) – a disorder in which the heart is unable to
supply enough blood to meet the demands of the body – could be assessed using SCG (and
PEP) responses to exercise measured with a wearable sensing system [76, 69, 23]. The
wearable system used for that study facilitates computation of PEP from electrocardiogram
(ECG) and seismocardiogram (SCG) signals [77]. The Q- or R-wave of the ECG signal
provides the timing information required for detecting the depolarization of the ventricles
(the start of the PEP interval); the Ao “peak” on the SCG signal provides the corresponding
timing for the aortic valve opening (AVO) (the end of the PEP interval) [46]. In this system,
the ECG is measured using three adhesive-backed gel (Ag/AgCl) electrodes, and the SCG
is measured using a low-noise, tri-axial micro-electromechanical systems (MEMS) based
accelerometer positioned at the middle of the sternum. Though promising results have been
obtained with this system both in healthy subjects and in patients with HF, there are sensing
and data analytics advancements that can potentially improve the accuracy with which PEP
is measured. First, recent work has shown that gyroscope based measurements of chest
wall vibrations may provide improved detection of heart and blood movement activity as
compared to accelerometers [78, 79, 60]. A rigorous investigation is needed comparing
gyroscope and accelerometer based SCG waveforms and the corresponding accuracy with
which PEP can be extracted. Second, while the opening of aortic valve may be read-
ily detectable from SCG signals in supine subjects, high inter-subject variability in SCG
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waveforms renders Ao peak detection inaccurate and ambiguous in many subjects standing
upright or walking. Novel machine learning approaches for combining multiple features
of gyroscope, accelerometer, and combined gyroscope and accelerometer based SCG mea-
surements can be employed to address this limitation. In this work we perform, for the first
time, a rigorous investigation of gyroscope and accelerometer based SCG measurement in
the context of PEP detection accuracy. We use a low-noise MEMS gyroscope with suffi-
ciently wide bandwidth to facilitate SCG measurement. We further leverage state-of-the-art
nonlinear and linear regression algorithms [80, 81] to map features of the SCG signal to
AVO, as detected by a reference standard signal—the impedance cardiogram (ICG) [82,
43]. In addition to single axis based estimates, we evaluate multi-axis and multi-sensor
fusion approaches to assess the possible corresponding improvement in PEP estimation.
Finally, we compare our PEP estimation approaches directly against several methods from
the existing literature. Fig. 4.1 shows a hypothetical system to estimate systolic timing
intervals from wearable sensors’ fusion using our estimation method.
4.3 Method
4.3.1 Experimental Protocol
The study was conducted under a protocol approved by the Georgia Institute of Tech-
nology Institutional Review Board. A total of 17 healthy subjects (7 females and 10
males) participated in the study (Age: 26.1±4.1 years, Weight: 66.2±13.6 kg and Height:
168.2±8.9 cm). All subjects provided written informed consent before experimentation
and reported no heart problems. The purpose of the protocol was to induce changes in PEP
non-invasively, and to then measure PEP with a reference standard (ICG) simultaneously
with different sensors under test. Regression algorithms were then applied to compare the
PEP estimation accuracy for these sensors under test compared to the reference standard.
Exercise was selected as the means by which PEP was modulated non-invasively because
it is known to change PEP substantially from the resting value in a relatively short period
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Figure 4.1: (a) Concept of a wearable device to monitor cardiovascular health parameters
and (b) proposed sensors and corresponding signals.
of time.
Fig. 5.3 (a) illustrates the placement of sensors on each subject. For each subject, the
middle point between the suprasternal notch and xiphoid process was located on the mid-
sternal line. The accelerometer was placed on top of the point and the gyroscope was
placed below the point. Both the sensors were attached using tape (Kinesio Tex, Kinesio,
Albuquerque, NM). After placing the wearable sensors, each subject was asked to step
on the modified weighing scale, which is capable of measuring ballistocardiogram (BCG)
signal. The subject was asked to stand vertically and motionless for five minutes. Then,
the subject performed three minutes of walking exercise at 3 miles per hour (mph) on a
treadmill followed by one and a half minutes of squatting exercise. After the full exercise
period, the subject stepped on the BCG scale again for monitoring the recovery period for
five minutes. The whole procedure was performed continuously, as shown in Fig. 5.3 (f).
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PEP decreased due to exercise and returned to baseline value of resting PEP during the
recovery.
4.3.2 Sensing Hardware
Linear and angular vibrations of the chest wall due to the heart beat were recorded using a
three-axis analog output accelerometer (ADXL354, Analog Devices, Inc., Norwood, MA)
and a three-axis differential analog output gyroscope (QGYR330HA, Qualtre Inc., Marl-
borough, MA) [83] respectively. Both the MEMS accelerometer and gyroscope have very
low noise and low drift. Fig. 5.3 (c) shows the linear and angular directions for the ac-
celerometer and gyroscope, respectively. The gyroscope’s differential outputs were passed
through an instrumentation amplifier (AD8226, Analog Devices, Inc., Norwood, MA) to
have one output signal per axis, shown in Fig. 5.3(b). BCG was measured simultaneously
using a previously validated modified weighing scale [65]. Seven outputs (three from the
accelerometer, three from the gyroscope and one from the scale) were connected to the data
acquisition system (MP150, BIOPAC System, Inc. Goleta, CA). ECG and ICG signals
were measured concurrently using BN-EL50 and BN-NICO wireless modules (BIOPAC
System, Inc., Goleta, Ca). Both signals were transmitted wirelessly to the MP150. The
sampling frequency for all the signals was 2 kHz.
4.3.3 Signal Processing and Feature Extraction
Linear Filtering and Pre-Processing: All the raw signals (accelerometer and gyroscope
based SCGs, ICG, BCG, and ECG) were filtered with finite impulse response (FIR) Kaiser
window band-pass filters (cut-off frequencies: 1-40 Hz for both the accelerometer and
gyroscope signals, 0.5-20 Hz for the BCG, 1-30 Hz for the ICG and 0.5-40 Hz for the
ECG). These cut-off frequencies were chosen based on the existing literature [77, 65, 84],
to remove out-of-band noise without distorting the shape of the signals. The same cutoff
frequencies were used for both gyroscope and accelerometer based chest vibration signals.
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Figure 4.2: (a) The experimental setup with the subject standing on the BCG scale, with all
other wearable sensors attached to the body. One accelerometer (ADXL354) and one gyro-
scope (QGYR330HA) are placed on the mid sternum. ECG and ICG signals are collected
simultaneously. (b) Circuit connection for the conversion of differential output of the gy-
roscope to single output per axis, using an instrumentational amplifier (AD8226). (c) Axis
labels used for the accelerometer and gyroscope, with accelerometer X axis in the head to
foot direction, Y axis in the side to side (lateral) direction and Z axis in the dorso-ventral
direction. Gyroscope X axis angular velocity corresponds to the rotation around head to
foot axis, Y axis angular velocity corresponds to the rotation around frontal axis and Z axis
angular velocity corresponds to the rotation around sagittal axis. (d) Block diagram of the
segmentation for ICG signal with reference R peaks from the corresponding ECG signal,
feature extraction from the ICG segments to calculate ground truth PEP. (e) Block dia-
gram of the segmentation for accelerometer and gyroscope signals with reference R peaks
from corresponding ECG signal, feature extraction from the segments to estimate PEP. (f)
PEP trend with the chronology of the experiment, 5-minute rest standing on BCG scale,
3-minute walk at 3 miles per hour speed, 1.5-minute of squats and 5-minute post exercise
standing on the scale. PEP remains fairly stable during the rest period, it decreases due to
exercise, and returns nearly to the baseline rest values during the recovery period.
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The signal-to-noise ratio (SNR) of the ECG was found to be very poor for one of the
subjects due to hardware issues, therefore data from this subject was discarded and data
from the other 16 subjects were used for further processing and analysis.
As most physiological measurements are corrupted by motion artifact during exercise,
which typically leads to higher noise, the signals recorded during exercise were discarded.
Since the goal of this analysis was to determine which features of SCG (accelerometer and
gyroscope) signals were most salient in PEP estimation, we decided rather to use only the
cleaner portions of the datasets – those corresponding to the initial 5-minute resting and
5-minute post-exercise recovery data. The signal processing and feature extraction were
performed in Matlab 2017b with a Macbook Pro Laptop with Core i5 dual core processor
and 16 GB of RAM and required approximately 54 minutes of processing time.
Ensemble Averaging: The R-wave peaks were detected on the ECG signal and all the
other signals (SCG, BCG, and ICG) were segmented into individual heartbeat frames using
the R peaks from the corresponding ECG signals, with a frame length equal to the minimum
R-to-R interval. With frame length equal to the minimum R-to-R interval, one frame con-
tained at a maximum one heartbeat by definition. In other cases, one frame contained less
than one heartbeat. Multiple frames were ensemble averaged to get averaged frames, which
reduced noise [85]. Five frames were averaged together to generate an ensemble averaged
frame, with an overlap of four frames between consecutive ensemble averages. This tech-
nique of averaging was used to maximize the number of ensemble averaged frames, with a
total of 13,993 heartbeat frames from 16 subjects.
Feature Extraction from ICG and BCG: The B-point and X-point of the ICG (dz/dt)
frames, were extracted based on [67]. The B-point was then used as the reference standard
AVO, and the ground truth PEP was obtained via calculating the R-B interval for every
ensemble average frames. A high level block diagram of this process is shown in Fig. 5.3
(d). The X-point of the ICG corresponds to the aortic valve closing (AVC). For BCG
frames, I, J and K peaks were extracted following the work of Inan et al. [65].
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Feature Extraction from SCG: For the accelerometer and gyroscope signals, initially
we extracted and analyzed different time domain, amplitude and frequency domain fea-
tures. Time domain features performed better in PEP estimation compared to amplitude
and frequency domain features as PEP itself is a time domain parameter. A total of 12
time domain features were chosen for detailed analysis in this work. These 12 features
per axis were extracted from each averaged frame by an automated algorithm and every
frame was visually checked to maintain the accuracy of the feature extraction. Features
extracted were as follows: largest and second largest maxima locations (0-250 ms), largest
and second largest maxima width (0-250 ms), largest and second largest minima location
(0-250 ms), largest and second largest minima width (0-250 ms), largest maxima location
(250-500 ms), largest maxima width (250-500 ms), largest minima location (250-500 ms),
largest minima width (250-500 ms). Peaks and valleys in the frame were ranked according
to their amplitudes, and the highest and second highest amplitude were used as the largest
and second largest maxima or minima accordingly. Location was calculated as the distance
from the corresponding R-peak in ms. Width was calculated as the width of the peak or val-
ley at half-prominence, in ms. We extracted eight timing features from the systolic portion
of the signal (0-250 ms) rather than putting emphasis on one location feature, to explore
how multiple points in the accelerometer and gyroscope signals are related to the AVO.
Although PEP is related to the timing features from the systolic portion of the signals, we
decided to explore features from the diastolic portion (250-500 ms) of the signals as well
and we have extracted four timing features from the diastolic portion of the signals.
4.3.4 Regression Models
Overall Framework: We trained a regression model to estimate the PEP using the features
extracted from the accelerometer and gyroscope signals described in Section II.C. For ev-
ery axis, M features were extracted from N ensemble averages. These features were placed
in an matrix A while the corresponding PEP values were placed in an vector bPEP. A re-
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gression model was trained on these to learn the relationship between A and bPEP. Resulted
trained model can then be used to estimate PEP for new heartbeat frames, from the features
extracted from the accelerometer or gyroscope signals. Fig. 5.3 (e) shows the high level
block diagram of the feature extraction and regression on the accelerometer and gyroscope
signals to estimate the PEP. The machine learning techniques, including various regression
models, were performed using Python 3.6 with the same laptop described in the later sec-
tion. It required approximately 20 to 60 minutes of processing time for different regression
techniques based on the parameters and features used.
XGBoost Regression: The majority of the research on SCG to estimate hemodynamic
parameters used conventional linear regression to relate the features from SCG to the esti-
mated parameter [60, 84, 86, 87, 88], with the underlying assumption that the relationships
are linear. However, the relationship between PEP and SCG features may not be linear as is
the case in most real data sets. That is, if we let Y represent PEP as a random variable and
X represent one of our features, it is unlikely that f(X)=E(Y|X) would be a linear function
in X [89]. Our aim was to evaluate whether a non-linear model performs better in estimat-
ing PEP compared to the standard linear models. Therefore, rather than using only linear
techniques, we leveraged Extreme Gradient Boosting (XGBoost) regression, which is a rel-
atively new machine learning algorithm that has recently gained popularity [81]. XGBoost
is a computationally efficient implementation of the gradient boosting machine learning al-
gorithm [90], and is an example of an ensemble method, combining multiple estimators to
predict a variable rather than using a single estimator [91]. It generates multiple regression
trees where errors from previous models are predicted by new models and are then added
together. It uses a gradient descent algorithm for this addition to minimize the loss and
these sequential additions are carried out until no further improvements can be made.
We used XGBoost regression (with hyper-parameter settings: learning rate=0.1, num-
ber of boosting rounds=200, column sampling factor=0.5, row sampling factor=0.5, reg-
ularization parameter (λ)=1) to estimate PEP using features extracted from different axes
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of the accelerometer and gyroscope based SCG signals and combination of multiple axes
from the same sensor or both the sensors. Estimated PEPs from different axes and from
different combinations of axes and sensors were compared using a variation of the repeated
cross-validation model assessment method discussed in [92].
Cross-Validation and Regression Model Evaluation: We first randomly paired the sub-
jects in our dataset, which consists of 16 subjects, into eight groups. We then performed
cross-validation by leaving one group (two subjects) out at each fold and trained an XG-
Boost regressor on the data from all subjects except the two that were left out. We then
predicted PEP for the left-out subjects and repeated this seven more times leaving a differ-
ent pair of subjects out each time. As a result, we have PEP predictions for all ensembles
from all subjects. The root mean squared error (RMSE) was then calculated between the








where N=13,993, the number of ensemble average frames from 16 subjects. We used
leave-two-out cross validation over leave-one-out cross validation to have more variation
in the training sets, and did not have enough subjects to leave more subjects out in the
cross-validation steps. We repeated the entire process 50 times with a new random pairing
of subjects each time. The cross-validation RMSE was calculated as the average of the
RMSE scores from 50 repetitions. In this way, we trained a global model rather than
multiple subject-specific models.
Regression for Multiple Axes: This approach was repeated for different axes of the
accelerometer and gyroscope and their combination, and we compared the resulting RMSE
scores. For the combination of multiple axes from the same or different sensors, features
from a pair of axes or multiple axes were combined using vector concatenation and were
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fed into regressors. The same cross-validation procedure was used to compute the RMSE.
We performed statistical analysis of the cross-validation results for single and multiple axes
comparisons.
Regression for BCG Signals: Three features (R-J interval, R-I interval and R-K interval)
from the ensemble averaged BCG frames were also used in similar fashion to develop
another global model following the same cross-validation step stated above, to estimate
PEP. Average RMSE from this model gave us the comparison between wearable sensors to
the scale based cardiac hemodynamics monitoring.
4.3.5 Feature Importance Evaluation
To generate global models of PEP estimation from the accelerometer and gyroscope sig-
nals, we trained XGBoost regressors using many features acquired from one or multiple
axes from one or both of the sensors. However, some of these features are more relevant to
PEP estimation than others. One advantage of using XGBoost (and other gradient boost-
ing methods) is that, it can provide feature importance estimates from a trained predictive
model. This importance indicates how useful each feature is in constructing the boosted
decision trees within the model [93]. Typically, the main node of a tree is divided based
on the most important feature whereas the deep nodes are divided based on less important
features. The feature importance values obtained from all of the decision trees within the
model are averaged to get the final relative feature importance scores. These scores can be
used to rank the features.
To evaluate which features generated from the accelerometer and gyroscope based SCG
signals contributed more to PEP estimation, we trained an XGBoost regressor on the com-
bination data set from all 16 subjects, with features from all the axes of the gyroscope and
accelerometer. The resulting regression model was then used to generate relative feature
importance scores as described above.
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4.3.6 Comparing Our Estimation with Existing Literature
We compared our PEP estimation method with recent PEP estimation methods used in
literature, where the researchers annotated specific points in the accelerometer and gyro-
scope signals using ECG as a reference signal and found those points to be well correlated
with the AVO [78, 60, 94, 95]. Tadi et al. [94] and Javaid et al. [95] used a fixed length
window of 90 and 200 ms respectively from ECG R peaks to find the AVO points in the
dorso-ventral SCG. Yang et al. showed that the maximum peak of the envelope of rotational
energy, calculated from the gyroscope signal, is close to the isovolumic moment (IM) of the
accelerometer signal, where IM is the minima immediately before AVO in the accelerom-
eter based dorso-ventral SCG signal [78]. Tadi et al. annotated the major maximum peak
in angular velocity around the head-to-foot axis (from the gyroscope signal) as AVO and
found strong correlation between the time interval between this point and corresponding
ECG R-peak with PEP from echocardiography [60]. We have used the aforementioned
algorithms to find AVO from the ensemble average heartbeat frames of corresponding ac-
celerometer and gyroscope signals, in our dataset. We have used the same cross-validation
method, described in Section II.E and calculated RMSE for each method to compare to our
methods.
4.3.7 Statistical Analysis
We performed statistical analysis on the cross-validated RMSE results to compare different
axes and combination of axes. In our cross-validation procedure which consisted of 50
repetitions, the random seed was fixed so that the subjects were paired in the same way in
the ith repetition, for all sensor axes/combinations. Multiple comparison tests were per-
formed on the RMSE results from the 50 repetitions to compare different axes and sensor
combinations. The Friedman test was performed to detect statistical differences if exist
and the Wilcoxon signed rank test was performed for post-hoc testing, on different axes
or combinations. Additionally, for the post-hoc testing Benjamini-Hochberg correction for
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multiple comparison was performed on the p-value. Details on these statistical tests and the
reasons behind their use are discussed in [96]. We performed similar procedure to compare
different regression techniques and to compare our method with different algorithms from
recent literature statistically. In this work, p-values below 0.05 were considered statistically
significant.
4.4 Results and Discussion
4.4.1 Intersubject Variability
A visual comparison of the complex nature and intersubject variation in signals from both
the accelerometer and gyroscope is shown in Fig. 4.3. AVO and AVC points, extracted
from corresponding ICG signals, are marked on these signals, demonstrating that the AVO
and AVC may not always correspond to specific points or patterns on the accelerometer
or gyroscope signal, as often stated in existing literature. Estimation of systolic timing
intervals based on this assumption might be error-prone and may work on a specific data
set or subject, but not for a global model.
4.4.2 t-SNE Visualization
The features extracted from the ensemble averaged frames were analyzed using machine
learning techniques. To visually compare the features generated using different axes and
combinations of axes of the accelerometer and gyroscope signals, t-SNE (t-Distributed
Stochastic Neighbor Embedding) [97] was used. The dimensionality of our data set, which
has twelve features (dimensions) per sensor axis, was reduced to two dimensions using
t-SNE. A scatter plot of the data was constructed where the two axes are the two t-SNE
dimensions and each point represents one ensemble averaged frame (Fig. 4.4). Each point
was colored according to the ground truth PEP of the frame to visualize the relationship
between the t-SNE dimensions and our target variable (PEP). If a particular feature has
information relevant to PEP, we would expect to see a pattern in the color distribution,
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Figure 4.3: Illustration of inter-subject variability in accelerometer and gyroscope signals
from rest data of 16 subjects, with AVO (B-point) and AVC (X-point) annotated from cor-
responding ICG signals. (Left) Ensemble average of 100 heartbeats of the accelerometer Z-
axis (dorso-ventral) signal and (right) ensemble average of 100 heartbeats of the gyroscope
X-axis (angular velocity around head-to-foot axis) signal. All the signals are normalized in
amplitude.
whereas if no relevant information is present, we would expect the colors to be randomly
distributed spatially in the plot. Examples where t-SNE is used to visualize the relationship
between a high dimensional feature space and a continuous variable can be found in [98,
99].
The t-SNE method considers pj|ithe probability that a data point xi would pick xj as its
neighbor, in high dimensions, as a similarity metric between data points. The similarity
metric between lower dimension counter parts of these points are denoted as qj|i which
is defined similarly to pj|i. The t-SNE algorithm finds a low dimensional embedding of
the data such that pj|i and qj|i remain similar [97]. We prefer t-SNE to other dimensional-
ity reduction techniques such as principal component analysis (PCA) or isometric feature
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Figure 4.4: Visual comparison of features from single axis and combination of axes from
the accelerometer and gyroscope signal, and features from BCG with target variable PEP
from ICG using t-Distributed Stochastic Neighbor Embedding (t-SNE): (a) plot for features
from z axis of the accelerometer, (b) plot for features from x axis of the gyroscope, (c) plot
for combination of features from x and z axes of the accelerometer, (d) plot for combination
of features from x and y axes of the gyroscope, (e) plot for combination of features from
x and z axes of the accelerometer and x and y axes of the gyroscope. (f) plot for features
from scale based BCG.
mapping (ISOMAP) because it was shown in the literature [99] that t SNE preserves the
details within the data structure better and minimizes local distortions. One limitation of
t-SNE is that it has computational complexity that is quadratic in the number of data points.
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To reduce computational time, our data points were down-sampled by a factor of three from
13,993 points to 4,664 points, which is sufficient for the purpose of t-SNE visualization.
Fig. 4.4 is showing the visual comparison among features from a single or combina-
tion of axes from the gyroscope and accelerometer with our target variable PEP. Features
from scale-based BCG are also shown in the figure to compare the wearable sensor with
the scale-based BCG. In case of the accelerometer and gyroscope, each data point corre-
sponds to all the features (12, 24 or 48 based on number of axes used) collected from the
ensemble averaged frames. In case of BCG each point corresponds to three features, ex-
tracted from the ensemble average frames of BCG. These multiple dimensions (features)
of data were reduced to two using t-SNE. Clear transition in the color pattern in the plots
for the combination of axes over random nature in the color pattern for the single axis (both
in the gyroscope and accelerometer) suggests that it is better to combine and use features
from multiple axes in estimating PEP than using one axis only. While BCG is showing
the best gradient in the color pattern, a combination of features from x and z axes of the
accelerometer and x and y axes of the gyroscope is showing a color pattern which is the
closest (compared to other four plots for single axis or pair of axes) to BCG.
4.4.3 Comparison and Combination of Accelerometer and Gyroscope
Table 4.1 shows the RMSE values in milli-seconds (ms) from different axes and their com-
bination from the gyroscope and accelerometer signals. Statistically significant differences
were found in these results according to Friedman test (p<0.05). Wilcoxon signed rank
test was performed on the different axes and their combinations to investigate where the
significance exists in post-hoc testing. When comparing single axes from the gyroscope
and accelerometer, the results showed that the x-axis of the gyroscope signals provided the
lowest RMSE of 12.63±0.49 ms in PEP estimation (Fig. 4.5 (a)) (p<0.05). RMSE from
y-axis of the gyroscope and z-axis of the accelerometer were similar (p>0.05). The z-
axis of the gyroscope yielded a slightly higher RMSE than the x-axis of the accelerometer,
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whereas the y-axis of the accelerometer provided the highest RMSE in PEP (p<0.05).
Table 4.1: RMSE (ms) for PEP estimates from single axis and combination of multiple


















For the linear acceleration components of the SCG signal, the most salient informa-
tion being derived from the z-axis from the accelerometer is consistent with the existing
literature [39], as the z-axis represents the dorso-ventral component of the signal – the
component that has been most commonly analyzed and demonstrated as being useful in
prior studies [77, 86, 53, 100]. For the rotational velocity components, the most salient
information being derived from the x-axis of gyroscope is consistent with the direction of
blood and heart movement inside the chest [101]. Prior imaging studies [101, 102, 103]
have shown that blood flow has a right hand helical pattern around the ascending aorta and
aortic arch at the beginning of systole: thus the most salient information being contained in
the x-axis of gyroscope, which represents rotational velocity around the head-to-foot axis
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Figure 4.5: (a) Comparison of RMSE in estimation of PEP using features from single axes
of gyroscope and accelerometer placed on the mid sternum, with RMSE in estimation using
BCG features as a reference. (b) Comparison of RMSE in PEP estimation using combina-
tion of features from multiple axes of the gyroscope and accelerometer, with RMSE from
BCG features as a reference. (c) Comparison of RMSE for PEP estimation using differ-
ent regression techniques. (d) Comparing RMSE in estimated PEP from our method with
RMSE calculated, using algorithms from recent literatures.
of the body, is as expected. Combination of axes from both the gyroscope and accelerom-
eter reduced the RMSE compared to single axis results (p<0.05) (Fig. 4.5 (b)). For the
gyroscope, combining the x and y axes provided lower RMSE than all three axes combined
(p<0.05), which suggests that adding features from the z-axis actually increases the error
in estimation of PEP; accordingly, the z-axis is not providing substantial information re-
garding PEP. In case of the accelerometer, combination of x and z axes provided the lowest
RMSE compared to the combination of all three axes (p<0.05), which suggests that the y-
axis from the accelerometer is not providing useful information regarding PEP. When axes
from both the gyroscope and accelerometer were combined, results show that the combi-
nation of x and y axes of the gyroscope and x and z axes of the accelerometer is providing
the lowest RMSE of 11.46±0.32 ms from all the axes and combination (p<0.05), whereas
combination of all the axes from both the sensors yields RMSE of 11.79±0.44 ms. This
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result is supported by the feature ranking of the best 15 features in estimating PEP, shown
in Fig. 4.6, where there are no features from the z-axis of the gyroscope and y-axis of the
accelerometer.
Figure 4.6: Ranking of the best 15 features from gyroscope (Gyro) and accelerometer
(ACC) in estimating PEP.
This feature ranking also shows that, out of 15 most contributing features in estimating
PEP, 10 features are from the gyroscope; this suggests that the gyroscope is contributing
more to PEP estimation compared to the accelerometer, in accordance with the work of
Migeotte et al. [59]. One interesting finding is that three out of 15 features are widths
of different peaks, which is suggesting that not only peak locations but also peak widths
should be considered in PEP estimation. Finally, three out of 15 features are from the
diastolic portion of the signals, which will require further studies to understand.
4.4.4 Comparison of Different Regression Technique
We hypothesized that non-linear regression models such as XGBoost regression would
perform better than linear regression models for estimating PEP from SCG features. To
address this hypothesis, we compared results obtained from the XGBoost regression on the
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combination of axes (x and z axes of the accelerometer and x and y axes of the gyroscope,
which showed the lowest cross-validated RMSE) to the same combination (same feature
set) but using other regression models.
We compared XGBoost regression to ordinary linear, Ridge, Lasso, random forest (RF)
and extra trees (ET) regression techniques. Ordinary linear, Ridge and Lasso are all linear
regression techniques, whereas XGBoost, RF and ET are ensemble learning algorithms.
Ensemble methods using regression tree estimators can fit complicated non-linear functions
robustly compared to linear models.
For Ridge and Lasso, the regularization parameter was varied between 10-3 to 102 loga-
rithmically. For RF and ET, regressors contained 200 trees and column sampling factor was
chosen as 0.5, similar to the XGBoost model parameters. For these ensemble models, each
tree was trained on a subset of features consisting of features. The cross-validated RMSE
results were compared for the different regression models, keeping the same features and
dataset and only the regression technique was altered.
As hypothesized, XGBoost produced the lowest RMSE (Fig. 4.5 (c), p<0.05) when dif-
ferent regression techniques were compared. Ordinary least squares regression resulted in
an RMSE that was 4 ms higher (p<0.05) compared to XGBoost. Linear regression results
does not improve with the introduction of L2 regularization via Ridge regression. Fig. 4.5
(c) is showing the result only for ridge=1. However, results did not change substantially for
the range of ridge values tested. L1 regularization via Lasso regression decreases RMSE
results by only 0.2 ms (p<0.05). Out of the three ensemble methods tested, RF regression
performed better than ET regression (p<0.05), while XGBoost performed the best.
As hypothesized, the relation between the extracted SCG features and PEP was bet-
ter characterized by non-linear models rather than linear ones, used in existing literature.
Ensemble methods produced lower RMSE compared to linear methods. Automatic feature
selection performed by the ensemble methods might be more effective than intrinsic feature
selection (due to shrinkage of regression coefficients) used in L1 or L2 regularization.
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4.4.5 Comparison with Algorithms from Existing Literature
Fig. 4.5 (d) shows the comparison of RMSE in estimating PEP using features via algo-
rithms from recent publications. As expected, PEP estimation using specific points on the
accelerometer or gyroscope is providing higher (more than 30%) RMSE compared to our
PEP estimation using combination of x and y axes of the gyroscope and x and z axes of the
accelerometer (p<0.05). RMSE was similar (p>0.05) for PEP estimation models based on
features following Javaid et al. [95] and Yang et al. [78].
These results demonstrate that emphasizing specific points (as in the existing literature)
from the accelerometer or gyroscope signal in estimating PEP can increase the error of
estimation in a global model, due to intersubject variation and complex morphology of
the signals. As a result, these approaches may not be applicable as a universal model
across subjects or across studies. As an alternative, our work suggests that general time
domain features from these signals can provide necessary information regarding PEP and
constitute a better-performing global model, which can reduce the complexity in feature
extraction techniques. Another point to note is that, in all four algorithms, researchers used
one peak/point from a single axis in the accelerometer or gyroscope signal, whereas we are
using combination of features from multiple axes from both the sensors.
4.5 Conclusion and Future Work
In this work, we have compared gyroscope and accelerometer based SCG signals and de-
veloped a global model to estimate PEP and compared our estimation with the ground truth
PEP extracted from a simultaneously-recorded ICG signal. We have demonstrated that the
combination of general time domain features from multiple axes of both accelerometer and
gyroscope provides a better estimation of PEP compared to the use of specific locations or
patterns from single axes of these sensors due to intersubject variability in these signals. In
the case of individual sensors, the gyroscope provided more valuable information regarding
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PEP compared to the accelerometer for our dataset, when the sensors are placed on the mid
sternum. It was also shown that the relationship between SCG signal features and PEP can
be modelled using ensemble learning techniques to develop the universal model. Finally,
this work highlights the advantages of sensor fusion for developing wearable sensors to
monitor cardiac health.
In this work, we collected data from healthy subjects and used the signals acquired from
the mid sternum only. Future work should look at the signals from different locations and
data from patients with cardiovascular diseases as well to assess how the model performs
with higher intersubject variability and take necessary measures to obtain more accurate
estimation of PEP. Exercise signals were not used for PEP estimation in this work. Future
work should focus on exercise data to assess the possible estimation of PEP during move-
ment with these regression methods. Gravity vector projection on different postures was
not considered in this work. Future work can take this into account and can use this as a
feature in the prediction model to see if it improves the prediction accuracy. Future work
should also focus on estimation of left ventricular ejection time, stroke volume, and other
cardio-mechanical parameters. In this work, we explored the relationship between PEP
and features from the diastolic portion of both accelerometer and gyroscope signal. Future
work can be conducted to investigate the underlying mechanisms.
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CHAPTER 5
WEARABLE PATCH-BASED ESTIMATION OF OXYGEN UPTAKE AND
ASSESSMENT OF CLINICAL STATUS DURING CARDIOPULMONARY
EXERCISE TESTING IN PATIENTS WITH HEART FAILURE
5.1 Overview
The aim of this work is to estimate oxygen uptake (VO2) from cardiopulmonary exercise
testing (CPX) using simultaneously recorded seismocardiogram (SCG) and electrocardio-
gram (ECG) signals captured with a small wearable patch. CPX is an important risk stratifi-
cation tool for patients with heart failure (HF) owing to the prognostic value of the features
derived from the gas exchange variables such as VO2. However, CPX requires specialized
equipment, as well as trained professionals, to conduct the study.
We have conducted a total of 68 CPX tests on 59 patients with HF with reduced ejection
fraction (31% women, mean age 55±13 years, ejection fraction 0.27±0.11, 79% stage C).
The patients were fitted with a wearable sensing patch and underwent treadmill CPX. We
divided the dataset into a training–testing set (n=44) and a separate validation set (n=24).
We developed globalized (population) regression models to estimate VO2 from the SCG
and ECG signals measured continuously with the patch. We further classified the patients
as stage D or C using the SCG and ECG features to assess the ability to detect clinical
state from the wearable patch measurements alone. We developed the regression and clas-
sification model with cross-validation on the training–testing set and validated the models
on the validation set. The regression model to estimate VO2 from the wearable features
yielded a moderate correlation (R2 of 0.64) with a root mean square error of 2.51±1.12
mL · kg–1 · min–1 on the training–testing set, whereas R2 and root mean square error on the
validation set were 0.76 and 2.28±0.93 mL · kg–1 · min–1, respectively. Furthermore, the
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classification of clinical state yielded accuracy, sensitivity, specificity, and an area under the
receiver operating characteristic curve values of 0.84, 0.91, 0.64, and 0.74, respectively, for
the training–testing set, and 0.83, 0.86, 0.67, and 0.92, respectively, for the validation set.
The result from this work shows that wearable SCG and ECG can assess CPX VO2 and
thereby classify clinical status for patients with HF. These methods may provide value in the
risk stratification of patients with HF by tracking cardiopulmonary parameters and clinical
status outside of specialized settings, potentially allowing for more frequent assessments to
be performed during longitudinal monitoring and treatment.
5.2 Introduction
A hallmark symptom of heart failure (HF) is exercise intolerance, which often manifests
through exertional dyspnea and fatigue. The degree of exercise intolerance is captured
by subjective assessments (New York Heart Association functional class), quality of life
questionnaires (e.g., Kansas City Cardiomyopathy Questionnaire, Minnesota Living with
Heart Failure questionnaire), and/or various objective exercise measures (e.g., 6-minute
walk distance). Cardiopulmonary exercise testing (CPX) is the most comprehensive exer-
cise test performed in clinical settings to quantify the degree of myocardial impairment and
pulmonary dysfunction [104, 105].
CPX has also evolved as an important diagnostic and prognostic tool to manage patients
with HF by elucidating mechanisms of exercise intolerance, quantifying disease progres-
sion, and facilitating recommendation for advanced therapies, such as heart transplantation
or ventricular assist device implantation [104, 105, 106, 107]. Peak oxygen uptake (VO2),
the slope of minute ventilation (VE) and carbon dioxide production (VCO2) and VO2 at
the anaerobic threshold are key CPX parameters that are used for this risk stratification and
disease status quantification. Although CPX is a valuable diagnostic and prognostic tool, it
requires a specialized environment and trained professionals to conduct the study. Accord-
ingly, although the information gained from CPX is valuable for patient assessment and
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titration of care, longitudinal CPX for patients with HF is cost-prohibitive, inconvenient,
and thus not feasible on a large scale. Using novel wearable technology, an unobtrusive and
inexpensive alternative to the CPX, with the ability to potentially garner similar informa-
tion as CPX from daily activities in home settings, could improve the remote monitoring
and management of patients with HF.
Recently, our team has developed a wearable device [77] capable of measuring electro-
cardiogram (ECG) and seismocardiogram (SCG) signals and atmospheric sensing (atmo-
spheric temperature, pressure, and humidity) and tested it in patients with HF [23]. The
SCG represents the chest wall movements associated with the movement of blood in the
heart and includes features representing the ejection of blood through the aorta [39]. Our re-
cent studies have shown that clinical status—degree of myocardial dysfunction and ability
to augment cardiac output for patients with HF—can be assessed using SCG after exercise
via pre-ejection period estimation and novel machine learning methodology [23, 76, 69].
However, although these results were promising, no group has demonstrated to date that an
HF clinical state can be accurately classified using wearable SCG and ECG signals or that
key parameters of cardiopulmonary function can be quantified from these signals.
In this work, we recorded ECG and SCG signals using an updated version of the pre-
viously validated wearable patch [77] simultaneously with CPX for patients with HF with
reduced ejection fraction (HFrEF). We extracted multiple features from these wearable
signals and estimated VO2 continuously throughout the course of exercise using state-of-
the-art regression algorithms. We then classified the clinical state of the patients based on
the changes in wearable signals associated with the exercise and compared the accuracy
of this classification against gold-standard clinical assessment based on CPX. The method-
ology of this work can be translated into monitoring cardiopulmonary health in patients
with HF for longitudinal remote home monitoring. Fig 5.1 shows a hypothetical system for
longitudinal monitoring of patients with HF using our wearable patch.
Following the work on estimating VO2 continuously using our custom-built wearable
43
Figure 5.1: Illustration of our envisioned three-step process for longitudinal monitoring of
HF patients: 1) Recording of SCG and ECG signals using a custom-built wearable patch
during exercise and daily activities. 2) Estimation of cardiopulmonary gas exchange vari-
ables and prediction of the clinical state of HF (stage C or D). 3) Intervention by a clinician
based on the longitudinal assessment of cardiopulmonary parameters and HF status (future
work).
patch, throughout the course of CPX for patients with HF, we translated similar method-
ology to estimate VO2 in a minimally controlled outdoor walking environment and in a
controlled treadmill exercise environment in healthy individuals. The follow-up study was
carried out to showcase the efficacy of the methods of the CPX study with wearable SCG
and ECG in tracking changes in VO2 in a daily living scenario. The follow-up study is
another important step towards facilitating remote monitoring of cardiopulmonary health.
5.3 Methods for CPX Study
5.3.1 Experimental Protocol
The CPX study in patients with HF was conducted under a protocol reviewed and approved
by the University of California, San Francisco, and the Georgia Institute of Technology
Institutional Review Boards. All patients provided written consent before the procedure.
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We have conducted a total of 68 CPX tests in 59 patients with HFrEF (with 9 patients
having 2 CPX tests separated by 253±117 days). All of the patients were recruited from
the cardiopulmonary stress test laboratory at the University of California, San Francisco.
Only patients with HFrEF and a body mass index of less than 40 were considered for this
study. We have separated the CPX tests into 2 groups of 44 CPX for a training–testing
set and 24 CPX for a separate validation set. The 24 CPX tests for the validation set were
obtained after the model was trained on the training–testing set.
Fig 5.2 (a) illustrates the experimental setup and placement of different sensors on each
patient. Before starting the procedure, normal skin preparation methods were administered,
and ECG leads were attached in a 12-lead ECG configuration. A gas exchange mask (Med-
graphics) was placed on the patient. A finger pulse oximeter, a forehead pulse oximeter,
and a blood pressure cuff were placed, and minimal baseline spirometry data were collected
to measure forced and slow vital capacity. The custom-built wearable device was placed
just below the suprasternal notch. After placing all the sensors, all wires were taped down
such that the patient could perform the protocol comfortably.
All CPX tests were performed on a treadmill (GE T2100) per the American College
of Cardiology/American Heart Association Guidelines [108] and following the modified
Naughton protocol [109]. Tests were terminated owing to general or leg fatigue, shortness
of breath, angina, dizziness, or electrocardiographic evidence of ischemia or arrhythmia.
Breath-by-breath measurements of respiratory rate, VE, VO2, VCO2, partial pressure of
oxygen, and partial pressure of carbon dioxide were collected at rest, at zero grade low-
speed walk, during exercise, and during recovery. Heart rate (HR), rhythm, and oxygen
saturation were continuously monitored with intermittent sphygmomanometry. ECG and
SCG signals were obtained continuously using the wearable patch.
As an outcome of the CPX tests, patients were classified as American College of Cardi-
ology/American Heart Association stage C HF (n=54) or stage D HF (n=14) based on the
recommendations from 2 HF physicians (Dr. Teresa De Marco and Dr. Liviu Klein from
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Figure 5.2: Experimental setup with wearable patch hardware and representative cardio-
genic signals. (a) The experimental setup with the patient walking on a treadmill, with all
the cardiopulmonary exercise testing measurement sensors and wearable patch attached to
the body. (b) The wearable patch top and bottom view with snaps for electrocardiogram
(ECG) electrodes and internal hardware. (c) Representative ECG and triaxial SCG signals
(head-to-foot [HtoF], dorsoventral [DV], and lateral [LAT]) from 1 patient in the study.
UCSF), following standard guidelines [108, 110, 111]. Patients were classified as stage D
HF if they were recommended for a heart transplant or ventricular assist device implant
based on their peak VO2 (<14 mL/kg/min or < 50% predicted if women or obese) and
VE/VCO2 ratio (>38 if respiratory exchange ratio was <1.05).
5.3.2 Sensing Hardware
Breath-by-breath data were collected using MGC Diagnostic/Medgraphics Ultima Series
with Breeze suite 8.1.0.54 SP7 (software version number). ECGs (12-lead) were collected
using GE Case V6.72. Pulse oximetry was measured using Radical 7 Masimo Rainbow
Set.
For all patients, the wearable ECG and 3 axis SCG signals (head-to-foot [HtoF], dorsoven-
tral [DV], and lateral [LAT]) were collected with a novel wearable patch as shown in Fig.
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1B. This patch is an improvement upon our previous version, as described in [77]. It
contains an ATSAM4LS microcontroller (Atmel Corporation, San Jose, CA), whereas the
previous version used an ATmega1284P microcontroller (Microchip Technology, Chan-
dler, AZ). The ECG sensor uses an analog-front-end-integrated circuit with an on-board
analog-to-digital converter ADS1291 (Texas Instruments, Dallas, TX). The accelerometer
in the present patch that acquires triaxial SCG signals is the ADXL355 (Analog Devices,
Norwood, MA), which has a low noise floor of 25 µg/
√
Hz compared to the triaxial ac-
celerometer BMA280 (Bosch Sensortech GmbH, Reutlingen, Germany) used in the previ-
ous version [77] with a noise floor of 120 µg/
√
Hz. The patch also contains a BME280
(Bosch Sensortech GmbH, Reutlingen, Germany) environmental sensor which records at-
mospheric pressure (AP), ambient temperature and relative humidity, whereas the previous
version [77] had only pressure sensing capability using the MS5611-01BA03 (Measure-
ment Specialties, Fremont, CA). The patch used in this work has a diameter of 7 cm and
weight of 38.2 gm. When fully charged, it can record continuously for approximately 45
hours, which is more than sufficient for constant remote monitoring. Initially it samples
the ECG signal at 1kHz, the accelerometer signals at 500 Hz and the environmental sig-
nals at 20 Hz, and saves the data into a SD card in the patch. A custom-built graphical
user interface accesses all the data into a computer and resamples the accelerometer and
environmental signals at 1 kHz to have the same sampling frequency of 1 kHz for all the
signals. Fig 5.2 (c) shows representative ECG and triaxial SCG signals from the wearable
patch. Fig 5.3 illustrates the overall workflow used in this work.
5.3.3 Data Analytics Techniques for Reducing Noise and Extracting Features from the
Wearable SCG and ECG Signals
Whereas the CPX equipment captures breath-by-breath VO2 data, the wearable patch cap-
tures one data point every 0.001 second (1 kHz sampling rate). A sliding window approach
was used to combine all of the values from the SCG and ECG signals for the period in
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Figure 5.3: Overview of the regression and classification techniques. (a) Wearable ECG
and seismocardiogram (SCG) (only showing 1 axis of the signal for simplicity) signals
were synchronized with breath-by-breath data from the CPX computer. R-peaks of the
ECG signal were detected, and the SCG signals were segmented into heartbeats using cor-
responding R-peaks. Ten heartbeat frames from the SCG signals were averaged to get
ensemble-averaged heartbeats corresponds to 1 oxygen uptake (VO2) value from breath-
by-breath data from CPX, and features were extracted from the averaged heartbeats. The
features were fed into a Random Forest regressor as estimators to estimate VO2. Estimated
VO2 was compared with actual VO2 to see the estimation accuracy. (b) The features from
SCG and ECG were fed into a support vector machine (SVM) classifier with radial basis
function kernel to estimate the clinical state of a patient and it was compared with the actual
clinical state derived from CPX.
between breaths to estimate a single VO2 value to compare against the gold standard. At
a high level, the approach to estimating VO2 was as follows: (1) the signals were prepro-
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cessed using our existing data analytics algorithms for SCG and ECG signals to decrease
motion artifacts and other noise; (2) representative features, or signal characteristics, we
hypothesized to be relevant for VO2 estimation were extracted from the SCG, and ECG
signals; and (3) regression models were trained to mathematically estimate VO2 from these
SCG and ECG signal features for all CPX instances in the training–testing set and later
validated in the validation set.
Preprocessing and ECG Artifact Removal: All the signals from the wearable patch
were synchronized with the breath-by-breath data from the CPX computer. The raw ECG
and SCG signals from the wearable patch were digitally filtered (cut-off frequencies: 0.5–40.0
Hz for the ECG and 1–40 Hz for the SCG signals) to remove out-of-band noise. After fil-
tering, a fourth SCG signal (SCGMag) was computed using vector summation on the 3
axes of the SCG. All the wearable signals were inspected for motion artifacts, and portions
of the signals corrupted by motion artifacts were excluded from the analysis.
Motion artifacts in the ECG signal can pose a major challenge to subsequent signal
processing and regression steps. Accordingly, an algorithm was implemented to detect and
remove artifact-corrupted segments of the signal automatically. Specifically, the ECG for
each 30-second-long frame was passed through an artifact detection function to choose the
window frame (i.e., length) of signal that is artifact-free (Fig 5.4). First, the upper (Eu) and
lower (El) envelope of the data is detected and a difference Ed (= Eu – El) is computed.
Then, the mean (µ) and standard deviation (σ) of Ed throughout the recording is calculated.
An artifact is defined as the signal segment when the Ed of that specific portion is greater
or less than 3σ from the µ. The longest artifact-free segment of the signal was chosen, and
the time stamp for this portion was used to segment all the wearable signals to obtain the
signals where high-quality ECG was present.
The ECG R-wave peaks were detected using a simple thresholding based peak detec-
tion method. The four SCG signals (SCGHtoF, SCGLAT, SCGDV, and SCGMag) were seg-
mented into individual heartbeats using the R-peaks from the ECG signals. Each heartbeat
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Figure 5.4: Automatic artifact removal of ECG: (a) Filtered ECG and SCG signals. (b)
ECG is passed through artifact detection algorithm. Segments with artifacts are chosen
when the difference (Ed) of upper (Eu) and lower (El) envelope of the signal is outside
the range of mean (µ) ± 3×standard deviation (σ) of Ed. The longest artifact free signal
segment is chosen and the time stamp of the start and end of that segment is calculated. (c)
Both ECG and SCG signals are segmented with the time stamps from the previous step,
where the ECG was found to be artifact free.
was windowed to a 600-ms duration from the R-peak. For each SCG signal, 10 consec-
utive heartbeats surrounding 1 VO2 measurement from the CPX hardware were averaged
time-point by time-point to obtain an ensemble-averaged heartbeat (Fig 5.3). Ensemble-
averaged heartbeats were computed across the whole recording with a step size of 1 heart-
beat. Ensemble averaging was used to reduce noise and motion artifacts within each heart-
beat [85]. This process resulted in a total of 46,673 ensemble-averaged heartbeats from 44
CPX instances in the training–testing set and 28,230 ensemble-averaged heartbeats from
24 CPX instances in the validation set. For each ECG signal, the R-to-R interval and in-
stantaneous HR were calculated for each heartbeat and averaged in the same way as the
ensemble-averaged waveforms. The average VO2 measurements corresponding to each
ensemble-averaged heartbeat were computed to be used as the target variables for each
ensemble-averaged heartbeat (i.e., the output variables against which the regression model
was trained).
Feature Extraction: The next step toward estimating VO2 from the measured signals
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involved extracting multiple features—or characteristics—that could then be input to a ma-
chine learning regression algorithm. A total of 17 frequency-domain features were auto-
matically extracted from each of the four SCG signals resulting in a total of 68 SCG features
per ensemble-averaged heartbeat. The SCG features extracted were as follows: total band
power (0-500 Hz), and band power in 3 Hz bandwidth frequency ranges from DC to 30
Hz. Additional frequency domain features were: the highest prominent frequency (fp1),
second prominent frequency (fp2), and third prominent frequency in the power spectral
density (PSD), and the amplitudes of the PSD at fp1, fp2, and fp3.
For prominent frequency, peaks in the PSD of the frame were ranked according to their
amplitudes, and the highest, second-highest, and third-highest amplitudes were used to
locate the first, second, and third prominent frequency accordingly. The averaged R-to-R
interval and instantaneous HR for each averaged heartbeat were used as ECG features.
SCG Outiler Heartbeat Removal: Before training a regression model to estimate VO2,
we removed outlier beats from the ensemble-averaged SCG heartbeats using the Maha-
lanobis distance [112]. For each subject, the first 50 averaged frames from the rest signal
were assumed as baseline frames and all the features (for a particular feature set) of the
50 frames were averaged to create baseline feature distribution. The Mahalanobis dis-
tance [112] was calculated between the baseline feature distribution and each averaged
heartbeat frame for a particular subject. The underlying hypothesis was that the wearable
signal would change in morphology with various intensity of exercise, and it would vary
the most at peak exercise compared to baseline, which would be reflected by the Maha-
lanobis distance. The first and third quartile (Q1 and Q3) were extracted, and the interquar-
tile range (IQR) was calculated as IQR=Q3-Q1, for subject-wise distribution. A particular
frame was considered as an outlier if the Mahalanobis distance of the frame is lower than
(Q1-1.5×IQR) or higher than (Q3+1.5×IQR) of the distribution. These outlier frames and
corresponding target variables were removed from the dataset. The distance calculated for
each frame was used as a feature in the regression model, which makes the total number
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of features equal to f+1. The signal processing and feature extraction were performed in
Matlab 2018a.
5.3.4 Regression and Classification
Regression Model: For each VO2 measurement recorded by the CPX equipment, a corre-
sponding set of features from the SCG signals was derived using methods described else-
where in this article. A regression algorithm was then designed and trained on the training
set to mathematically estimate VO2 from this set of features using part of the recorded data
as a training set and the remainder of the data as a testing set. Specifically, we trained a
Random Forest (RF) [113] regression algorithm to estimate VO2 from the wearable signal
features and used leave-one-subject-out (LOSO) cross-validation [114] to evaluate the es-
timation accuracy. For all 44 CPX instances in the training–testing set, at each fold—or
iteration of the cross-validation process—an RF regression model was trained on the data
from 43 patients (thus leaving 1 CPX instance out) to learn the relationship between fea-
tures from the wearable sensors and the target variable VO2. The resulting trained model
was then used to estimate the corresponding VO2 values for the heartbeat frames from the
left out CPX instance. This procedure was repeated 43 more times, leaving a different CPX
instance out each time. This cross-validation method was used to develop a global regres-
sion model with optimized hyperparameters on the data in the training–testing set only. For
the validation of the global model, the regression model (with the optimized hyperparame-
ters) was trained on the whole training–testing set (all 44 CPX instances) and tested on the
separate validation set (with 24 CPX instances). As a result, we obtained predictions of all
target variables from all ensemble-averaged heartbeats, from all 68 CPX instances.
Two figures of merit that are commonly used in the existing literature were used to
evaluate the regression model and approach. First, the root mean squared error (RMSE)
was calculated for each left out CPX instance: specifically, the error between the estimated
VO2 values and the CPX equipment measured VO2 values across all breaths. The cross-
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validated RMSE was then calculated as the average of the RMSE scores from 44 folds in
the training–testing set and 24 CPX instances in the validation set. Second, the coefficient
of determination (R2) between the true values and the cross-validated predictions of VO2
across all CPX instances were calculated for the training–testing set and the validation set
separately.
To assess the benefit of using a combined SCG/ECG approach for predicting VO2, the
RF regression approach was repeated for 3 different feature sets: the SCG features only, the
ECG features only, and the combined SCG and ECG features. We compared the resulting
cross-validated RMSE scores to assess the performance of each feature set to estimate VO2.
We performed statistical analysis on the cross-validation results from the different feature
sets.
To understand the value of the information provided by SCG signals and our ma-
chine learning algorithm compared with the ECG-derived HR for estimating instantaneous
VO2, we trained an RF regression model using SCG signal features alone and a second
model with HR alone using a simple linear regression model as used in literature to in-
vestigate the VO2–HR relationship [115, 116]. We performed the same LOSO cross-
validation and calculated the cross-validated RMSE. We performed statistical analyses on
the cross-validation results to compare the SCG signal feature-based model with the HR-
based model.
Classification: In addition to estimating VO2 using regression, we aimed to assess the
ability to classify each patient’s clinical status based on the wearable sensing data measured
during treadmill exercise using classification. We used a machine learning classification
technique to classify the patients with HF as stage C or stage D on a particular CPX pro-
cedure day using the wearable measurement alone and compared the estimated class with
the true class based on the CPX outcome. Specifically, a support vector machine classi-
fier with a radial basis function kernel [117, 118] was used, and classification performance
was evaluated using LOSO cross-validation in the training–testing set and later validated
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on the separate validation set similarly as described in the regression model section. We
preprocessed the wearable features before using them in the classifier. The details on the
preprocessing of the wearable features for the classifier are given below.
For each subject, ensemble-averaged heartbeats were ranked from lowest to highest us-
ing corresponding Mahalanobis distance (described above) for a particular subject and the
highest 100 heartbeats were chosen for each subject for further classification analysis, giv-
ing us a total of 4400 heartbeats from 44 subjects. The underlying hypothesis of choosing
the highest 100 heartbeats was that the subjects were classified based on the peak exercise
capacity during CPX, and wearable signal segments correspond to peak exercise capacity
would reflect the difference between stage C and stage D subjects. These heartbeats were
labeled for each subject based on the true class for that particular subject.
Similar to the regression analysis approach with the training–testing set, for the clas-
sification task, the classifier was trained on the features from 43 of the 44 CPX instances
to map the features into an output of stage C and D state. We then used this classifier to
predict the class of each heartbeat frame for the left-out patient. The majority vote (i.e.,
class) of the heartbeats was chosen as the predicted class for the patient on that particu-
lar CPX procedure day. We repeated these steps 43 more times, leaving a different CPX
instance out each time. In this way, we obtained a predicted class for all CPX instances.
Similarly, for the validation set, we trained the classification model (with hyperparameters
tuned in the training–testing set of the classification task) on all 44 CPX instances in the
training–testing set and estimated the class of each CPX instances in the validation set.
Finally, we compared the estimated class to the true class of the patients from the corre-
sponding CPX outcome to calculate classification performance for the training–testing and
validation set separately. The machine learning techniques for regression and classification
were performed using Python 3.6.
Estimation of Peak VO2: Because the peak VO2 is among the key parameters extracted
from a CPX procedure to assess the clinical status of the patients, we tried to see how our
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regression model, which estimates instantaneous VO2, can be used in estimating peak VO2
as well. The maximum of the estimated VO2 values for a particular CPX instance was used
as the estimated peak VO2 value for that CPX and compared with the true measured peak
VO2 from corresponding CPX procedure, in a correlation and a Bland–Altman analysis.
We have calculated the percentage error between estimated and true values of peak VO2
and reported the average of the percentage error. We have used values from all 68 CPX
instances, including both the training–testing and the validation CPX instances.
Peak HR-Based Regression and Classification: To understand the potential added
value from SCG signals and our machine learning approach beyond peak HR alone, we
have directly studied peak HR-based correlation and classification for the same dataset.
We performed a simple correlation analysis (without any cross-validation) between peak
VO2 and peak HR. Further, we also applied exactly the same methodology (regression
model with cross-validation) as for SCG-based peak VO2 estimation and formed a model
for estimating peak VO2 from peak HR alone. In addition to the regression analysis, we
classified the patients based on peak HR alone into stage C and stage D, in exactly the same
manner we applied to our SCG-based features.
5.3.5 Statistical Analysis
We performed statistical analysis on the cross-validated RMSE results to compare regres-
sion results from different feature sets. Multiple comparison tests were performed on the
RMSE results from the cross-validation. The Friedman test was performed to detect if sta-
tistical differences exist, and the Wilcoxon signed-rank test was performed in post hoc test-
ing for pairwise comparison. Additionally, for the post hoc testing, Benjamini–Hochberg
correction for multiple comparison was performed on the P values. The demographics of
patients in stage C and stage D were compared using the Student t-test. In this work, P
values of less than .05 were considered statistically significant.
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5.4 Methods for Healthy Subject Study
5.4.1 Experimental Protocol and Hardware
For the follow-up study with healthy individuals, we conducted the study under a protocol
(H18452) approved by the Georgia Institute of Technology Institutional Review Board. A
total of 17 healthy subjects (9 females and 8 males) participated in the study (Age: 26.8
± 4.1 years, Weight: 67.5 ± 14.1 kg and Height: 170.5 ± 9.9 cm). All subjects provided
written informed consent before experimentation and reported no cardiopulmonary issues.
To record the gold-standard VO2 for this follow-up study, we used a COSMED K5
(COSMED, Rome, Italy) metabolic system. The same wearable patch, used in the CPX
study, was used in this follow-up study with healthy individuals. Fig. 5.5(a) shows the
placement of both sensors: our custom-built wearable patch and the COSMED K5 metabolic
system. Fig. 5.5(b) shows the custom-built wearable sensor hardware, which measures
ECG, triaxial SCG, and environmental features (atmospheric pressure, temperature, and
humidity). For each subject, we placed the wearable sensor evenly between the supraster-
nal notch and xiphoid process on the mid-sternal line, using three ECG electrodes (model
2670, 3M, Saint Paul, MN, USA). For the COSMED K5 system, we fitted subjects with a
gas exchange mask on their face and the K5 system on their back. We situated a heart rate
belt from the K5 system just below the chest line. After fitting subjects with all the sensors
and systems, we asked them for confirmation of their comfort before testing. At the start
of each trial, we synchronized both the wearable sensor and K5 system to a smart mobile
phone in order to record timestamps throughout the protocol.
Fig. 5.5(d) shows the outline of the study protocol, which we divided into two parts:
a treadmill walking portion in a laboratory setting and an outdoor walking portion in an
uncontrolled setting. For the treadmill part of the protocol, subjects first stood still for
two minutes to record baseline data. Then, subjects walked on a treadmill at five different
speed settings (0.75, 1, 1.25, 1.5 and 1.75 meters/second, roughly 1.7, 2.2, 2.8, 3.4 and 4
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Figure 5.5: (a) A subject configured with both the wearable patch and the COSMED K5
system, with inset showing a zoomed-in image of the ECG electrodes. (b) The wearable
patch top, bottom, and inside. The microSD (1), microUSB (2), and battery (3) are shown.
(c) A map of the outdoor walking route across Georgia Institute of Technology with marked
terrain. (d) An outline of the study protocol.
miles/hour) for six minutes at each speed, totaling 30 minutes of walking. After completing
the treadmill walk, subjects stood still for 5 minutes to record a recovery period. Including
this recovery period, subjects performed the treadmill protocol continuously for a total of
37 minutes.
After the treadmill part, subjects rested for 15 minutes before starting the outside walk-
ing protocol. They began this section standing still for 2 minutes at the “Start/Stop” location
of the route marked in Fig. 5.5(c). Then, subjects walked the route shown in Fig. 5.5(c),
arriving back at the same “Start/Stop” point. The route contains a mixture of level ground,
uphill and downhill walkways (with significant slopes), two uphill stairs climbing, and four
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traffic signals along the way. The terrain is marked in Fig. 5.5(c). Subjects completed this
walk at their own chosen speed and followed normal pedestrian traffic laws. After complet-
ing the route, subjects stood still for 3 minutes to record a recovery period. This part of the
protocol took approximately 20-30 minutes depending on each subject’s speed as well as
traffic conditions during their testing. Of 17 subjects, two females were not able to perform
the outside walk due to precipitation. For that reason, we obtained data from 17 treadmill
protocols and 15 outdoor protocols.
For this study, we recorded the gold standard breath-by-breath (BxB) metabolic data
with the COSMED K5 system (COSMED, Rome, Italy). Subjects wore the COSMED
heart rate probe (i.e., belt), which provided an HR reading corresponding to the ground-
truth metabolic data.
We collected ECG and triaxial SCG (axes: head-to-foot (HtoF), dorso-ventral (DV),
and lateral (Lat)), with the same wearable patch described in the method section of the
CPX study, shown in Fig. 5.5(b).
5.4.2 Signal Processing and Regression
For signal processing of the BxB data and wearable sensor, we followed similar procedures
(ECG artifact removal, heartbeat segmentation, and ensemble averaging), as mentioned
for the CPX study. For SCG feature extraction, we extracted a couple of more time and
amplitude features on top of the frequency domain features mentioned above in the CPX
study.
Using an automated algorithm, we extracted 28 time domain, 17 amplitude, and 17 fre-
quency domain features (62 total) from the ensemble-averaged waveforms for each of the
four SCG signals. The list of extracted features is provided in Table. 5.1. We extracted
the amplitude and time domain features from the time-domain representation of the SCG
signals, and the frequency domain features from the power spectral density (PSD) estimate
of the SCG signals. Peaks and valleys in the averaged frames were ranked according to
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their amplitudes, and the highest and second-highest amplitudes were used. The location
was calculated as the distance from the corresponding R-peak in ms. The width was calcu-
lated as the width of the peak or valley at half-prominence, in ms. We evaluated different
combinations of feature sets for performance in estimating VO2





Highest and second highest peak
(Ampl., Loc. and Width)
2 4
Lowest and second lowest valley
(Ampl., Loc. And Width)
2 4
Number of peaks and valleys 2
First and second peak (Ampl., Loc.
And Width)
2 4
First and second valley (Ampl.,
Loc. And Width)
2 4
Highest peak of absolute signal




Highest peak (Ampl., Loc. and
Width)
1 2
Lowest valley (Ampl., Loc. And
Width)
1 2
Number of peaks and valleys 2
Highest peak of absolute signal
(Ampl., Loc. And Width)
1 2
SCG AUS (0-100 ms), ..., (400-500 ms) 5
SCG PSD Band
Power
(0-3 Hz), (3-6 Hz), ..., (27-30 Hz)
and (0-500 Hz)
11
SCG PSD First, second and third prominent
frequency (Ampl. and Freq.)
6
Single Axis Total 17 28 17
4-Axes Total 68 112 68
Ampl: amplitude, Freq: frequency, Loc: location, AUS: area under signal, PSD:
power spectral density.
Regression Model: For the regression model in the follow-up study, we chose an ex-
treme gradient boosting (XGBoost) regression [81] from our initial analysis in this work.
XGBoost is a decision-tree based ensemble algorithm that uses a gradient boosting [119]
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framework. It is an example of an ensemble method [91] that is computationally effi-
cient, parallelizable, able to handle missing values, and able to be pruned/regularized to
avoid over-fitting. We fit an XGBoost regressor on the extracted features for all ensemble-
averaged heartbeats to estimate corresponding target VO2 values. We then used this model
to estimate VO2 values for unseen heartbeat frames as represented by the same feature sets.
We performed this process with different combinations of feature sets extracted from the
SCG, ECG, and AP signals, optimizing hyper-parameters with a grid search. The final
hyper-parameters are as follows: learning rate=0.05, max depth=10, subsample=0.6, col-
sample bytree=0.7, n estimators=100, min child weight=2, gamma=0.3. We used Python
3.6 for all machine learning techniques.
Statistical Analysis: We performed the same statistical tests to compare the perfor-
mance of different feature sets of SCG and ECG to estimate VO2, as described in the CPX
study method section.
5.5 Results and Discussion from CPX Study
Patient demographics and clinical characteristics for the CPX study are detailed in Table 5.2
and CPX characteristics are provided in Table 5.3.
5.5.1 Regression Model Comparison
Fig 5.6 (a) shows the correlation analysis between the actual (measured) VO2 and the esti-
mated VO2 using the combined features from SCG and ECG for the training–testing set and
Fig 5.7 (a) shows the corresponding analysis for the validation set. For the training–testing
set, the regression model with the SCG features only performed better in estimating VO2
compared with the model using ECG features only: RMSE of 2.55±1.16 mL · kg–1 ·min–1
vs 3.75±1.68 mL · kg–1 · min–1, respectively (P< .001) and a corresponding R2 of 0.63 vs
0.19. Combining SCG and ECG features improved the estimation accuracy slightly com-
pared with SCG features only, but the improvement was not significant (P>.05) with an
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RMSE of 2.50±1.12 mL · kg–1 · min–1 and an R2 of 0.64.










Age, years 54.53 ± 12.68 54.81±12.88 53.43±12.28 0.53
Sex
Male 47 (69%) 40 (74%) 7 (50%)
Female 21 (31%) 14 (26%) 7 (50%)
Height, cm 172.4±9.14 172.67±9.34 171.4±8.57 0.59
Weight, kg 87.99±18.39 87.57±17.96 89.59±20.63 0.68
BMI, kg/m2 29.53±5.26 29.27±4.85 30.51±6.73 0.37
Ejection fraction,% 27.25±10.64 26.21±9.29 31.29±14.46 0.13
NYHA class
I 12 (13%) 12 (18%) 0 (0%)
II 24 (30%) 22 (36%) 2 (0%)
III 32 (57%) 20 (45%) 12 (100%)
Orthopnea 17 (27%) 13 (27%) 4 (27%) 0.73
Bilateral leg edema 12 (20%) 8 (18%) 4 (27%) 0.23
Systolic blood pressure,
mmHg
105±15 105±14 102±19 0.41
Diastolic blood pres-
sure, mmHg

























































































11(16%) 7 (13%) 4 (29%) 0.16
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Values shown are mean±standard deviation or n (% of population) or mean±standard deviation
(% of population) unless otherwise indicated. Statistical significance between stage C and D
patients in values, where applicable, was evaluated using an unpaired t test or a χ2 test.
ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin
receptor blocker—neprilysin inhibitor; BNP, B-type natriuretic peptide; CPX, cardiopulmonary
exercise testing; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro b-
type natriuretic peptide; NYHA, New York Heart Association; OHT, orthotopic heart transplan-
tation; VAD, ventricular assisted device implantation.
∗Number of CPX test instances with available laboratory results.
aSubsequent events were recorded up to 6 months after the completion of the study. In the cases
where 1 cardiopulmonary exercise testing patient had multiple events (e.g., VAD, followed by
transplant later), only the first occurring event was counted as subsequent events for a particular
patient.
In the case of the validation set, similar results were obtained using SCG and ECG
features separately: RMSE of 2.28±1.04 mL · kg–1 · min–1 vs 3.52±1.5 mL · kg–1 · min–1,
respectively (P < .001) and a corresponding R2 of 0.76 vs 0.36. Similarly, combining the
SCG and ECG features improved the estimation accuracy (RMSE of 2.28±0.93 mL · kg–1 ·
min–1 and R2 of 0.76) slightly compared with SCG features only, although the improvement
was not significant (P > .05).
In the case of comparing SCG features with ECG-derived HR in estimating instanta-
neous VO2, SCG features resulted in a significantly higher R2 of 0.63 compared with 0.31
using HR only for the training–testing set (P < .05), and correspondingly 0.76 compared
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Peak VO2, ml/kg/min 15.58±4.82 17.21±3.92 9.32±1.93 <0.001
Percent predicted peak
VO2, %
58±21 63±20 37±9 <0.001
VE/VCO2 slope 33.35±6.65 32.44±6.48 36.82±6.34 0.04










12.02±3.68 12.91±3.47 8.59±2.24 <0.001
Peak respiratory exchange
ratio
1.05±0.12 1.07±0.11 0.96±0.12 0.002
Exercise duration, s 672±235 743±200 401±148 <0.001
Peak heart rate, beats/min 120.06±23.8 124.57±22.79 102.64±19.77 0.002
Values shown are mean±SD. Statistical significance between stage C and stage D subjects in values,
where applicable, was evaluated using an unpaired t test
∗Number of CPX instances with detectable AT points, Modified V-slope method was used to detect
the AT points.
Figure 5.6: Regression and classification results on the training–testing set. (a) Correlation
analysis between VO2 predicted vs VO2 actual for the training and testing set. (b) The blue
curve is showing the receiver operating characteristic (ROC) curve for the support vector
machine (SVM) classifier with a radial basis function kernel for the training and testing set.
The red line is the ROC curve for classification based on random chance. The area under
the blue ROC curve (AUC) is 0.74.
with 0.25 using HR only in the validation set (P < .05). The corresponding RMSE values
were 2.55±1.16 (SCG) vs 3.58±1.54 mL · kg–1 · min–1 (HR) for the training–testing set
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and 2.28±1.04 (SCG) vs 3.66±1.74 mL · kg–1 · min–1 (HR) for the validation set.
Figure 5.7: Regression and classification results on the validation set. (a) Correlation anal-
ysis between VO2 predicted vs VO2 actual for the validation set. (b) The blue curve is
showing the ROC curve for the SVM classifier with radial basis function kernel for the
validation set. The red line is the ROC curve for classification based on random chance.
The AUC of the blue ROC curve is 0.92.
5.5.2 Classification
Table 5.4 and Table 5.5 show the classification results using the support vector machine
with a radial basis function kernel for the training–testing and validation sets, respectively.
Accuracy, sensitivity, and specificity obtained for the training–testing set were 0.84, 0.91,
and 0.64, respectively, whereas for the validation set, they were 0.83, 0.86, and 0.67 re-
spectively. Fig 5.6 (b) and Fig 5.7 (b) show the receiver operating characteristics curve
of the classifier with an area under the curve of 0.74 and 0.92 for the training–testing and
validation sets, respectively.
5.5.3 Peak VO2 Estimation
Fig 5.8 shows the correlation analysis and Bland–Altman analysis between measured and
estimated peak VO2 values using SCG and ECG features for all 68 CPX instances, with a
percentage error of 20.74% and an R2 of 0.5.
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Table 5.4: Confusion Matrix for Classification on the Training-Testing Set
n=44 Predicted Stage C Predicted Stage D
Actual Stage C 30 (TP) 3 (FN) 33
Actual Stage D 4 (FP) 7 (TN) 11
34 10
TP = True Positive, FN = False Negative, FP = False Positive, TN= True Negative
Accuracy = 0.84, Sensitivity = 0.91, Specificity = 0.64, Positive predictive value = 0.88 and
Negative predictive value = 0.7
Table 5.5: Confusion Matrix for Classification on the Validation Set
n=24 Predicted Stage C Predicted Stage D
Actual Stage C 18 (TP) 3 (FN) 21
Actual Stage D 1 (FP) 2 (TN) 3
19 5
Accuracy = 0.83, Sensitivity = 0.86, Specificity = 0.67, Positive predictive value = 0.95 and
Negative predictive value = 0.4
Figure 5.8: Results of peak VO2 estimation. (a) Correlation analysis and (b) Bland–Altman
analysis between predicted peak VO2 vs actual peak VO2 for all 68 CPX instances used in
the study.
5.5.4 Peak HR-Based Regression and Classification
The correlation analysis between the peak VO2 and the peak HR resulted in an R2 of 0.23
for all 68 CPX instances. In contrast, estimation of the peak VO2 using the peak HR using
the same regression model and LOSO cross-validation approach used with SCG features
resulted in an R2 of 0.19 between the measured and estimated peak VO2 values for all 68
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CPX instances. The Bland–Altman confidence interval was calculated to be 17.1 mL · kg–1
· min–1 in this case. In the case of classifying the patients based on peak HR alone into
stage C and stage D HF, the resultant area under the curve values for the receiver operating
characteristics curve were 0.59 for the training–testing set and 0.54 for the validation set.
5.5.5 Discussion
With this proof-of-concept study, we have shown the potential of a small, lightweight,
wearable patch capable of measuring SCG and ECG to estimate beat-by-beat VO2 estima-
tion throughout a standard CPX procedure. Our results have shown that features from the
wearable patch may capture the changes in cardiopulmonary demand during exercise and
may be used to differentiate between stage C and stage D HFrEF. These promising initial
results provide a foundation for determining cardiopulmonary variables and the clinical
status of patients with HF in their daily life and activities using wearable sensors. With
further research, this approach could enable remote monitoring of these patients outside
clinical settings.
An important finding in this work was that the features from the SCG signal were more
salient in estimating VO2 as compared with the ECG signal. Many Holter-type patches
are currently available for ECG measurement and have been used in studies for monitoring
patients with HF [41, 42]. Additionally, smartwatches are commercially available and can
measure HR and possibly HR variability (provided there is minimal motion artifact). Al-
though such commercially available tools are convenient and readily applicable to studies
in patients with HF, the results from this article demonstrate that HR-based features may
not provide sufficient value in assessing cardiopulmonary health in patients with HF dur-
ing exercise. Rather, approaches using a combination of ECG- and SCG-based sensing are
needed such that VO2 and a patient’s clinical status can be accurately determined during
exercise. This result is consistent with our prior work [23], where changes in the SCG sig-
nal in response to a 6-minute walk test were found to be more salient in assessing clinical
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state for patients with HF than ECG or HR features alone.
Another important, and perhaps surprising, finding in this work is that the signal qual-
ity of the SCG signals measured during treadmill exercise in patients with low signal levels
overall (patients with HF) was sufficiently high to enable accurate estimation of VO2. The 2
main factors allowing such high signal quality to be obtained during exercise from a signal
that has typically been limited to low motion/vibration environments only were the follow-
ing: (1) the improved wearable patch we have developed that was used in this work employs
the lowest noise microelectromechanical system accelerometer available, with a noise floor
that is 2.5 times lower than any other microelectromechanical system accelerometer used
in prior studies to the best of our knowledge; and (2) the direct coupling of the patch to
the chest wall at the sternum with a triangular configuration of ECG electrodes provides a
rigid and robust mechanical interface to the body from which SCG signals can be reliably
recorded, even in the presence of motion artifacts. Thus, the results of this work may form
a foundation upon which future efforts focused on assessing the mechanical aspects of left
ventricular function during movement can be designed and realized.
From the result with peak VO2 estimation, it is apparent that the model underestimated
and overestimated peak VO2 for very high and low values of measured peak VO2, respec-
tively. This limitation is well-known in machine learning-based models, because it will try
to produce results close to the overall mean of the distribution rather than extreme values.
Increasing the number of patients with a broader spectrum of exercise capabilities may de-
crease the estimation accuracy for the extreme peak VO2 values in future studies. Also, a
point to note here is that the regression model presented here was trained to learn the un-
derlying relationship of SCG and ECG features with beat-by-beat VO2, not only peak VO2.
Maximal effort covers only a small portion of the CPX protocol. This can be attributed
to the comparatively lower performance of peak VO2 estimation in our analysis compared
with the estimation of the beat-by-beat estimation of VO2.
Although the measurement of VO2 values at less than peak may not currently be clin-
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ically relevant, one can imagine that with the capability of estimating VO2 accurately for
submaximal exercise tasks, such as walking upstairs or outdoors, the ability to assess pa-
tients with HF outside of clinical settings may be enhanced. Thus, in future clinical care
scenarios where digital data collection methodologies are being leveraged, the measure-
ment of VO2 in submaximal tasks could potentially become an important and clinically
relevant capability.
Comparing the results of peak VO2 estimation using our method with peak HR-based
method demonstrates that augmenting HR with cardiomechanical features may result in
a higher correlation coefficient and smaller confidence interval for estimating peak VO2.
The SCG signal features resulted in a more robust classification performance for separat-
ing patients with stage C and D HF as well. Future work should focus on improving the
estimation accuracy of peak VO2 from wearable SCG and ECG signals.
The peak VO2 was used along with the VE/VCO2 ratio to determine the severity of HF
(stage C and D) in these patients. In our regression analysis, the algorithm was trained to
learn the underlying features of the SCG and ECG signals to estimate instantaneous VO2
throughout the CPX protocol, whereas the classification algorithm was trained to learn
the underlying features of the SCG and ECG signals to determine the severity (stage C vs
stage D) of HF for these patients. The regression model can be used to estimate VO2 during
submaximal exercise levels as well as maximal effort, whereas classification tasks can give
1 label to the whole CPX test. These preliminary findings, however, need verification in
a larger patient population with a variety of exercise levels. Because peak VO2 played a
key role in determining the true class of the patients, there can be some common SCG and
ECG features that were used by both regression and classification models. Future work
should examine both SCG and ECG features from both maximal and submaximal exercise
to relate to the severity of HF and investigate the underlying physiological relationship
between them.
It should also be noted that, although the regression and classification approaches used
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in this work are “black box,” as is the case for any machine learning technique, the relative
importance of SCG frequency domain features vs. ECG-HR features does provide some
insight into possible physiologic mechanisms behind the relationship between SCG signals
and VO2. Specifically, the changes in the frequency domain characteristics of the signals
might suggest the presence of nonlinearity (i.e., harmonics) in the vibrations of the chest in
response to the heartbeat at higher levels of exercise and VO2. Another potential mechanis-
tic link could be in the relationship between some frequencies of the SCG signal and stroke
volume, which is an important factor constituting VO2. Nevertheless, these mechanistic
links are conjecture at this point and should be investigated in the future using studies with
direct hemodynamic measurements (e.g., right heart catheterization) taken simultaneously
with SCG signals to characterize the origin and characteristics of the signal in the context
of left ventricular function and health.
This study also has several limitations that should be noted. Our dataset had only 21%
patients with stage D HF (25% in the training–testing set and 13% in the validation set),
resulting in higher peak VO2 for patients with stage D HF. For a few cases of patients
with stage C HF with a very high peak VO2compared with the rest of the population, our
model underestimated their VO2 and corresponding peak VO2 estimation. In future studies,
we will increase the number of patients and incorporate patients with a broader spectrum
of exercise capabilities, which may decrease the estimation error for these extreme cases.
Similarly, our classification model classified 30 of 33 stage C CPX instances accurately,
whereas 7 of 11 stage D CPX instances were accurately classified in the training–testing set.
For the validation set, it classified 18 of 21 stage C CPX instances accurately, whereas 2 of
3 stage D CPX instances were accurately classified. The comparatively poor performance
in the classification of patients with stage D HF can be associated with a smaller number of
patients with stage D HF (n=14) in our dataset, the shorter duration of exercise compared
with patients with stage C HF, and greater pathophysiologic differences among patients
owing to various HF-related diseases. Increasing the number of patients with stage D HF
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in future studies should increase the classification accuracy for patients with stage D HF as
well.
This preliminary study demonstrated the potential of using advanced machine learning
algorithms to estimate continuous VO2 throughout the CPX procedure and clinical status
of patients with HF, both in a training–testing set and a separate validation set. Results in
the validation set were comparatively better than the training–testing set. One reason can
be that our validation set had fewer patients with stage D HF by chance compared with the
training–testing set, and our model performed well for the patients with stage C HF because
it has more patients with stage C HF to learn from in the training phase. Incorporating more
patients with stage D HF in future studies should verify these initial findings in a large set
of population pool.
In this work, we have only estimated VO2. Future work should focus on estimating
other gas exchange variables (e.g., VCO2, VE, and tidal volume) from the CPX and to
investigate the underlying mechanisms. Additionally, we have collected data only from
patients with HFrEF. Future studies can assess the efficacy of this sensor in patients with
HF with preserved ejection fraction. In addition, these tests were performed in a controlled
clinical setting with trained professionals. The data from home or an unsupervised setting
may be of lower quality compared with the data obtained here. Future studies can elucidate
whether wearable SCG and ECG parameters measured during normal activities of daily
living can be predictive of the parameters measured during extensive CPX.
5.6 Results and Discussion from Healthy Subject Study
5.6.1 Comparison of Different Feature Sets of SCG with ECG
Table. 5.6 shows the RMSE in ml/kg/min and R2 values for different combinations of fea-
ture sets extracted from the wearable signals. Statistically significant differences existed in
these results, according to the Friedman test (p<0.05). We performed Wilcoxon signed-
rank tests on the different feature sets to investigate the significance of their differing ac-
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curacy values. All the feature sets described in this table included an AP signal feature
(except HR-based linear regression model) in addition to the features explicitly stated.
Table 5.6: RMSE (ml/kg/min) and R2 for VO2 estimation from different feature sets of SCG
(Amplitude, Ampl, Frequency, Freq and Time, Time ) and ECG using XGBoost, and HR
using linear regression model
Treadmill Protocol Outside Walking Protocol
Feature Set RMSE R2 RMSE R2
Ampl 4.06±1.06 0.76 4.8±1.53 0.52
Freq 3.68±0.98 0.77 4.85±1.31 0.57
Time 5.42±1.39 0.45 5.13±1.18 0.45
ECG 7.48±1.83 0.17 5.81±1.07 0.4
Ampl+ECG 4.24±1.18 0.72 4.46±1.56 0.58
Freq+ECG 3.99±1.28 0.71 4.30±1.47 0.64
Time+ECG 5.07±1.79 0.5 4.89±1.66 0.47
Ampl+Freq 3.78±0.98 0.78 4.79±1.53 0.54
Ampl+Time 4.04±1.27 0.68 4.93±1.62 0.47
Freq+Time 3.9±1.33 0.67 4.92±1.41 0.48
Ampl+Freq+ECG 3.98±1.27 0.75 4.52±1.52 0.59
Ampl+Time+ECG 4.27±1.54 0.64 4.81±1.67 0.48
Freq+Time+ECG 4.27±1.61 0.61 4.69±1.65 0.51
Ampl+Freq+Time 3.87±1.18 0.73 4.95±1.57 0.47
Ampl+Freq+Time+ECG 4.12±1.4 0.68 4.75±1.66 0.5
HRa 6.31±1.72 0.44 5.94±1.76 0.35
aA simple linear regression model was used for HR only. For other feature sets, XGBoost
regression model was used to generate the reported results.
As shown in table 5.6, of the single SCG feature sets, frequency domain features
achieved the lowest RMSE and highest R2 for the treadmill protocol. Amplitude fea-
tures were slightly worse (p>.05), and time-domain features performed the poorest (p<.05
compared to both frequency and amplitude). For the outdoor protocol, frequency features
achieved the best R2 and had an RMSE only slightly above (p>.05) that of amplitude fea-
tures (with a narrower confidence interval). Time-domain features once again performed
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Figure 5.9: (a) Correlation analysis for VO2 predicted vs VO2 actual (b) Bland-Altman
analysis for VO2 predicted and VO2 actual for treadmill exercise. (c) Correlation analysis
for VO2 predicted vs VO2 actual (d) Bland-Altman analysis for VO2 predicted and VO2
actual for outside walking exercise. In the Bland-Altman plots, the solid black line indicates
the mean while the blue dashed lines indicate mean ± 1.96 x standard deviation.
the worst, though not significant (p>.05). From these results it appears that frequency do-
main features provided the most salient information for estimating VO2 from SCG in both
settings.
Better performance of frequency domain features in the estimation of VO2 is under-
standable as exercise leads to substantial changes in the shape and timing of waveforms.
For example, the shortening of isovolumetric contraction time associated with increased
sympathetic tone compresses the SCG waveform in time and thus increases high-frequency
components [77]. VO2 relates to Stroke Volume [120], which has been shown to have a re-
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lation with the amplitude features of the SCG signal [39]. This result is consistent with
[121, 23], where researchers have used frequency-domain features of the SCG signal to
assess clinical state for patients with HF. When comparing the frequency and amplitude
features, frequency features performed slightly (p>0.05) better. Our results show that
exercise-induced changes of VO2 change not only the amplitude of the SCG signals but
also the signal power at different frequency bands. Frequency domain features captured
these changes better than amplitude features.
ECG features alone performed worse than all three SCG features alone in both protocols
(p<0.05 compared to all three feature sets of SCG for the treadmill protocol and p<0.05
compared to amplitude and frequency feature sets of SCG for the outside walking protocol),
using XGBoost regression algorithm. As other studies have demonstrated high linear corre-
lations between HR and VO2 [122, 123, 115, 124], the comparatively poor performance of
ECG features (instantaneous HR and R-to-R interval) in our approach is likely attributable
to the overly-complex nature of an XGBoost regression model and/or the addition of the
R-to-R interval feature. To compare our results with the common HR-based approach, we
also fit a simple linear regression model with HR only to estimate instantaneous VO2 using
the same LOSO cross-validation approach, which achieved an RMSE of 6.31±1.72 and
R2 of 0.44 for the treadmill protocol and an RMSE of 5.94±1.76 and R2 of 0.35 for the
outside walking protocol. Still, these results are significantly poorer (p<0.05) compared to
the amplitude and frequency domain features of SCG. Separate from the HR-based simple
linear regression model with LOSO cross-validation, we also performed a simple correla-
tion analysis between instantaneous HR and VO2 across all subjects, which resulted in an
overall R2 of 0.49 and 0.42 for the treadmill and outside walking protocol, respectively.
A similar analysis on each subject individually resulted in a higher R2 of 0.73±0.11 and
0.71±0.16 for the treadmill and outside walking protocol, respectively. The lower value of
the global R2 compared to the subject-wise R2 is in agreement with existing literature [115,
124]. For this reason, researchers often use %VO2-max and %HR-max when attempting
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to show population-level relationships between VO2 and HR rather than their raw values
directly [115, 124, 125, 126, 127]. Overall, these results show the benefit of incorporating
cardio-mechanical information from SCG into a complex machine learning algorithm for
the development of a global regression model to estimate instantaneous VO2 compared to
simple linear models involving only HR-based information.
When combining different feature sets of SCG with ECG in XGBoost regressors, we
achieved our best results (i.e., lowest RMSE and highest R2) on the treadmill protocol using
amplitude and frequency features of SCG (RMSE of 3.78±0.98 ml/kg/min and R2 of 0.78),
which is significantly lower (p<0.05) than amplitude features alone. Still, the lowest RMSE
for the treadmill protocol was obtained using frequency-domain features alone (RMSE of
3.68±0.98 ml/kg/min with frequency-domain features alone vs. 3.78±0.98 with amplitude
and frequency domain features together, p>0.05). For the outdoor protocol, we obtained
our best results using frequency features of SCG and ECG features (RMSE of 4.30±1.47
ml/kg/min and R2 of 0.64). These results were significantly better (p<0.05) than those
from frequency, amplitude, time, and ECG features alone. Best results in RMSE and R2
values for each protocol are shown in bold in Table 5.6. Fig. 5.9 provides a correlation
analysis and Bland-Altman analysis of actual VO2 values and estimated VO2 values, using
the feature set with the lowest RMSE for each protocol. It is apparent that regression
models can generally estimate instantaneous VO2 well on a heartbeat by heartbeat basis.
Fig. 5.10 shows examples of best and worst estimations of VO2 compared to actual
VO2 for both protocols. The same model used in Fig. 5.9 generated the VO2 estimations
here. Even when achieving the worst results in both protocols, as shown in Fig. 5.10 (b)
and (d), the algorithm still tracks relative changes well despite overestimating overall VO2
values. Hence, we see a consistent offset between actual and predicted values in both cases.
From Table. 5.6 in the case of the treadmill protocol, adding ECG features indepen-
dently to both the amplitude feature set and the frequency feature set increased the error
in both cases. This is as expected because the performance of ECG features was the worst
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Figure 5.10: Example of subject-wise VO2 prediction for both exercise tasks: (a) Best case
scenario and (b) worst case scenario for treadmill exercise. (c) Best case scenario and (d)
worst case scenario for outside walking exercise.
among all the feature sets for the treadmill protocol. For the outside walking protocol,
adding ECG features reduced the RMSE for these same two feature sets (p<0.05). For
better VO2 estimation, the selection of feature sets for a global model should incorporate
domain knowledge of cardio-electromechanical responses to ranges of exercise and activ-
ity.
Overall from Table 5.6, the estimation results were better for the treadmill protocol
than for the outside walking protocol. This is expected as the treadmill protocol took place
indoors with standardized speeds and conditions, whereas the outside walking protocol
was completed at the subject’s pace with variable atmospheric conditions depending on the
day. Future studies should examine wider varieties of exercise with subjects of broader
age range and health status to apply this methodology in estimating instantaneous VO2
throughout daily activities.
5.7 Conclusions
We have demonstrated that a wearable chest patch-based sensor capable of recording ECG
and SCG may be used to estimate VO2 from CPX for patients with HF using a global re-
gression model and may facilitate the determination of the clinical state of the patient. We
have also demonstrated that the patch-based sensor is capable of estimating VO2 in uncon-
trolled daily life activities with healthy individuals. We thus demonstrated that wearable
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sensors can potentially be used to monitor cardiopulmonary health and to stratify disease
risk for patients with HF both in an inpatient and in an outpatient management system.
The approach described in this work may thus provide the capability to perform longitu-
dinal CPX testing for patients with HF in clinical and hospital settings such that treatment
and management can be titrated and personalized based on physiologic state. Because CPX
testing has been established as a valuable technique in assessing patient state for HF, broad-
ening the ability to perform such testing in longitudinal patient management may improve
the quality of care and life for patients with HF. Future studies should verify these prelim-
inary findings in a larger patient population with a wider spectrum of exercises, in both a
clinical environment and normal daily living activities.
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CHAPTER 6
TRACKING CHANGES IN PULMONARY CONGESTION WITH
SEISMOCARDIOGRAM DURING RIGHT HEART CATHETERIZATION WITH
VASODILATOR CHALLENGE IN PATIENTS WITH HEART FAILURE
6.1 Overview
Tracking changes in pulmonary congestion and the consequent proactive readjustment of
treatment plans have shown efficacy in reducing rehospitalization for patients with HF.
However, the cost-prohibitive nature of these sensing systems precludes their usage in
the large patient population affected by HF. In this study, we estimated the changes in
pulmonary artery mean pressure (PAMP) and pulmonary capillary wedge mean pressure
(PCWMP) due to vasodilator infusion during right heart catheterization, using changes in
wearable SCG. We have collected data from 19 subjects with HF, and using a population
regression model estimated the changes in PAMP and PCWMP with the changes in si-
multaneously recorded SCG. The leave-one-subject-out cross-validated result shows good
estimation accuracies for both: an RMSE of 2.6 mmHg and R2 of 0.77 for estimating
changes in PAMP, and an RMSE of 2.2 mmHg and R2 of 0.88 for estimating changes in
PCWMP. The result of this work shows that changes in SCG can be used to track changes
in pulmonary congestion due to vasodilator infusion.
6.2 Introduction
The increased filling pressure of the heart is an early indicator of the onset of worsening HF
[25]. Continuous monitoring of PA pressure using an implantable sensor (CardioMEMS)
to track the increased filling pressure of the heart and adjustments of care (i.e., titration
of medications, early follow-up clinic visits, etc.) have shown efficacy in reducing read-
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mission for patients with HF [19, 128, 129]. CardioMEMS (CardioMEMS HF System,
Abbott, Chicago, IL) is a microelectromechanical system (MEMS) based pressure sensor
that is implanted in the pulmonary artery and which sends the pulmonary artery pressure
once per day to the clinicians [24] and the clinicians can change the course of the treatment
(by titrating medication) based on the pulmonary congestion to keep the pulmonary artery
pressure within a recommended limit [19]. This proactive adjustment of care has been
shown to reduce the HF-related readmission by 33%.
Another recent technologies from Sensible medical (Netanya, Israel), remote dielectric
sensing (ReDS), also tracks the pulmonary congestion (lung fluid content) via measuring
the dielectric properties of the thorax (with the sensor placed on the right mid- thorax)
non-invasively and has shown efficacy in reducing HF-related rehospitalization by 87%
and 79% compared to pre- and post ReDS guided therapy in a clinical study consists of 50
patients with HF[22]. Both of these technologies have shown the importance of tracking
pulmonary congestion (a biomarker for tracking the filling pressure of the heart) as an early
indicator of the worsening HF condition and the efficacy of hemodynamically-guided HF
management system to reduce hospitalization. However, costs related to both the device (>
$25,000 for CardioMEMS and $48,000 for ReDS) make them financially non-accessible
for the large patient population affected with HF in the US, which is roughly 6.2 Million
Americans [130]. For that reason, a low-cost alternative that can track changes in pul-
monary congestion has the potential to help millions of people affected with HF not only
in the US but also in the whole world.
With the advent of MEMS-based sensors and digital health technologies, various wear-
able monitoring systems have been explored by the clinicians and researchers to monitor
cardiovascular health both in healthy individuals and patients with HF. One such method-
ology is Seismocardiogram (SCG), the local vibration of the chest wall due to the cardiac
cycle, which has shown to track cardiac contractility with exercise and physiological pertur-
bation [76, 131, 95]. Recent studies have shown that SCG can be used to classify patients
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with decompensated HF [23, 121]. Based on these results on SCG in tracking hemodynam-
ics for both healthy individuals and patients with HF, we hypothesized that the changes in
pulmonary artery pressure (PAP) and pulmonary capillary wedge pressure (PCWP) could
be tracked with changes in SCG signal.
In the current work, we recorded SCG and ECG signals from patients with HF using
a previously validated custom-built wearable patch during the right heart catheterization
(RHC) [132] procedure, which is a gold standard clinical procedure to measure pulmonary
congestion via measuring pulmonary artery pressure (PAP) and pulmonary capillary wedge
pressure (PCWP). During the RHC procedure, the PAP and PCWP were modulated via
infusing systemic vasodilator, and changes in the mean pressure values were estimated via
tracking the changes in simultaneously recorded SCG signals. We have analyzed various
portions of the SCG signals to understand the important segments that are providing more
relevant information regarding changes in PAP and PCWP.
6.3 Methods
6.3.1 Experimental Protocol
The study was conducted under a protocol reviewed and approved by the University of
California, San Francisco, and the Georgia Institute of Technology Institutional Review
Boards. All patients provided written consent before the procedure. We have conducted
the RHC procedures on a total of 19 patients with HF (14 with HFrEF and 5 with HF-
pEF, four female, age: 55±14, weight: 92±18 kg, height: 175±10 cm, ejection fraction
[EF]: 32±19). All of the patients were recruited from the Catheterization laboratory at the
University of California, San Francisco.
Fig 6.1 (a) illustrates the experimental setup and placement of different sensors on each
patient. Before starting the RHC procedure, the custom-built wearable device was placed
just below the suprasternal notch, and the RHC computer was time-synchronized with the
wearable patch.
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Figure 6.1: (a) Experimental setup with a wearable patch placed on a subject undergoing
right heart catheterization (RHC) procedure, with axes (on the upper-right) showing the
axes of the seismocardiogram (SCG) signal. (b) Representative cardiogenic signals: elec-
trocardiogram (ECG), triaxial SCG (head-to-foot [HtoF], lateral [Lat], and dorsoventral
[DV]), and RHC pressure (RHCP) signal. (c) Wearable patch top, bottom, and inside view
with the bottom view showing the snaps for ECG electrodes.
For beginning the RHC procedure, a local anesthetic agent was administered subcu-
taneously at the access site. To access the venous, an 18-gauge needle was inserted in
the femoral/jugular site, and once the venous access was obtained, an appropirately sized
sheath is placed in the vein and secured. A pulmonary artery swan-ganz catheter [133] was
advanced through the sheath into the vein and guided to the right atrium, right ventricle,
pulmonary artery, and pulmonary capillaries following standard protocol [134]. The blood
pressure values at different intra-cardiac and pulmonary chambers were recorded at the end
of expiration from the RHC computer. When the baseline pressure values were recorded, a
systemic vasodilator (nitroprusside/nitroglycerin) was infused and the RHC pressure values
were again recorded at the end of expiration. When all the pressure values were recorded,
the catheter was taken out from the veins, and subjects were monitored for post-procedure
recovery. The wearable ECG and SCG signals were recorded continuously throughout the
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RHC procedure, and the timestamps from both the RHC and wearable system were used
to extract the specific portions of the wearable signals later in the analysis, to estimate
the changes in PAP and PCWP from the changes in wearable signals. Fig 6.1 (b) shows
the wearable signals with corresponding PAP signal from the RHC computer during the
baseline RHC recording from a representative subject.
6.3.2 Sensing Hardware
RHC pressure values were extracted by the expert RHC clinicians from the RHC Mac-Lab
computer (Mac-Lab Hemodynamic Recording System, GE Healthcare, Chicago, IL, USA).
We collected the wearable ECG and triaxial SCG (axes: head-to-foot (HtoF), dorso-
ventral (DV), and lateral (Lat)), with the same wearable patch described in Chapter 5, as
shown in Fig. 6.1(c). All the ECG and SCG signals were sampled at 1kHz.
6.3.3 Signal Procecssing and Feature Extraction
Fig. 6.2 illustrates the signal processing and feature extraction procedures used for the
wearable signals and the pressure signal from the RHC computer. Both the system were
time-synchronized before the procedure was started. The PA mean pressure (PAMP) and
PCW mean pressure (PCWMP) values for both the baseline (BL) and during vasodilator
infusion (VI) were extracted by the expert clinicians and later used to calculate the changes
in PAMP (δPAMP) and changes in PCWMP (δPCWMP) using the following equations:
δPAMP = PAMPVI − PAMP BL (6.1)
δPCWMP = PCWMPVI − PCWMP BL (6.2)
The PCWMPVI value for one subject was not recorded due to a technical issue in the
Mac-Lab system. For that reason, the δPCWMP value is missing for that subject. In total,
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we had δPAMP values from 19 subjects and δPCWMP values from 18 subjects for this
study protocol.
The synchronized timestamps were used to extract 20 seconds long wearable signals
(ECG and SCG) from both BL and VI state of the protocol when the catheter was at the
pulmonary artery and pulmonary capillaries. The changes in the wearable signals were
analyzed with the δPAMP and δPCWMP values and later used in a population regression
model with cross-validation. The details of the wearable signal processing, feature extrac-
tion, and regression model are given below.
Preprocessing and Noise Reduction
The BL and VI wearable signals were processed (filtering, removal of outliers, and en-
semble averaging) separately and later used to calculate the dynamic time warping (DTW)
distances between the two states. The DTW distances between different portions of the
SCG signals from different axes were used in a regression algorithm to estimate δPAMP
and δPCWMP with leave-one-subject-out (LOSO) cross-validation.
The raw ECG and SCG signals from the wearable patch were digitally filtered (cut-off
frequencies: 0.5–40.0 Hz for the ECG and 1–40 Hz for the SCG signals) to remove out-
of-band noise. We chose these cut-off frequencies to remove out-of-band noise without
distorting the shape of the signals [131]. After the filtering step, we computed a fourth
SCG signal representing the accelerometer magnitude (SCGMag) using the three SCG axes
already obtained (SCGHtoF, SCGLat, SCGDV) according to the following formula:
SCGMag =
√
(SCGHtoF2 + SCGLat2 + SCGDV2) (6.3)
We amplitude normalized the ECG signal (in the 20-second frame) and used the Pan
Tompkins method [135], [136] to detect the R-peaks of the ECG signal. We segmented the
SCG signals (four axes of SCG) into individual heartbeats using the R-peaks of the ECG
signal. We cropped each heartbeat to a duration of 500 ms before and after the R-peak. The
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Figure 6.2: Overview of the method: (a) Wearable ECG and SCG (only showing one axis of the
signal for simplicity) signals were synchronized with the RHCP signal. 20s long signals from both
baseline (BL) and during vasodilator infusion (VI) were extracted when the catheter was recording
pulmonary artery (PA) pressure and in pulmonary capillary wedge (PCW) pressure signals. (b)
The R-peaks of the ECG signal were detected and later used to segment the corresponding SCG
signals into individual heartbeats. Outlier removal and noise reduction steps were performed on the
SCG heartbeats, and features were extracted to be used in the regression algorithm to estimate the
changes in the RHC mean pressure (MP) values (e.g., changes in pulmonary artery mean pressure
[δPAMP], and changes in pulmonary capillary wedge mean pressure [δPCWMP]). The MPBL and
MPVI values were extracted from the RHC Mac-Lab computer and used to calculate the target
variable (δPAMP and δPCWMP). (c) Details on the wearable signal processing: First, the R-peaks
of the ECG signals were detected, and the SCG signals were segmented into individual heartbeats.
Second, SCGBL and SCGVI heartbeats were passed through an outlier removal algorithm (using
principal component analysis [PCA] and Gaussian mixture model [GMM]) and were ensemble-
averaged to have two average SCG heartbeats per axis (one for BL and one for VI). Third, dynamic
time warping (DTW) distances were calculated between the BL and VI heartbeats per axes and used
as features (f) in the regression algorithm.
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500 ms SCG frame before the R peak roughly represents the ventricular diastolic phase, and
the 500 ms SCG frame after the R peak roughly represents the ventricular systolic phase
of the cardiac cycle, as described in Fig. 2.3. We chose the duration of 500 ms before and
after the R-peak based on our previous experience with SCG signals and generic feature
extraction processes [131], as most of the relevant diastolic and systolic cardiac events of
interests (e.g., rapid inflow, atrial systole, isovolumetric contraction, ventricular ejection,
etc.) occur within this time frame, with respect to the corresponding R-peak of ECG. We
chose a constant time window to crop the ECG and SCG signals to have a repeatable and
generic feature extraction process.
Following the heartbeat segmentation of the wearable SCG signals, we removed the
outliers beats from the SCG for the two distribution from the two states (BL and VI) for
each axis and each portion (diastolic and systolic) of the SCG signals separately. For out-
lier removal from a particular distribution, we reduced the dimension of the 500 sample
long SCG heartbeats (for 500 ms long frame with a 1kHz sampling frequency) into three
dimensions by using principal component analysis (PCA) and taking the first three princi-
pal components (PC). This low-level representation of the SCG heartbeats was used in a
Gaussian-mixture model (GMM) to determine the probability that each sample belongs to
a particular distribution (BL or VI) for a particular portion and a particular axis of SCG.
For a particular distribution, the points with the lowest 20% probability were detected as
the outlier for the distribution. The cut-off of 20% was chosen based on the initial anal-
ysis with 10%, 20%, and 30% beats removed as outliers. As most of the power in the
SCG signal stays in the systolic portion of the signal [39], it might end up dominating
the outlier removal in the diastolic portion of the signal. For that reason, the outlier re-
moval was performed separately for the diastolic and systolic portion of the SCG. The
actual SCG heartbeats correspond to the outliers for the distribution were removed and re-
sulted in two separate distribution per axis (SCGBL and SCGVI). The remaining heartbeats
were ensemble-averaged [85] to create two ensemble-averaged heartbeats for BL and VI
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for a particular axis and portion, which were later used to calculate the DTW distances.
The ensemble-averaging step reduced the inherent variabilities and remaining noises in the
SCG heartbeats. Fig. 6.3 shows the ensemble-averaged SCGDV heartbeats from the BL and
VI states and corresponding PAP and PCWP heartbeats.
Dynamic Time Warping and Feature Extraction
To calculate the changes in SCG from BL to VI, we have used dynamic dime warping
(DTW) and compare the DTW distances from different portions of the SCG heartbeats to
the δPAMP and δPCWMP in simple correlation analyses, shown in Fig. 6.4. The DTW is
a time-series analysis method to align signals and find similarities between signals [137].
We have used Euclidean distances as the DTW-based distance calculation between signals
from BL and VI. The DTW distances were calculated from different portions of the SCG
heartbeats: total diastole (-500ms:R-peak), early diastole (-500ms:-200ms), late diastole
(-200ms:R-peak), total systole (R-peak:500ms), early systole (25-150 ms), and late systole
(200-500ms), where negative time means before the R-peak and positive time means after
the R-peak. Early diastole corresponds to the passive ventricular filling, late diastole corre-
sponds to the atrial systole, early systole corresponds to isovolumetric contraction (IVC),
and late systole corresponds to the ventricular ejection phase of the cardiac cycle, as de-
picted in Fig. 2.3. We compared the DTW distances from the different portions of SCG
heartbeats with the target variable in a simple correlation analysis (shown in Fig. 6.4) and
calculated the coefficients of determination (R2) between them to analyze which segments
of the SCG are more relevant to track changes in PAMP and PCWMP. Later, we used the




Following the feature extraction and simple correlation analysis, a population level re-
gression model with LOSO cross-validation was performed to estimate the δPAMP and
δPCWMP from the DTW distances. We explored different regression algorithms for this
purpose, and from our initial analysis, the Ridge regression model outperformed other re-
gression methods. For that reason, we chose the ridge regression model for detailed anal-
ysis in this work. The Ridge regression method belongs to the class of linear regression
models with l2 regularization where the loss function is the linear least-squares function,
and the regularization is given by the l2-norm [138].
As we have seen in the simple correlation analysis (Fig. 6.4) between the DTW dis-
tances from different portions of the SCG heartbeats and corresponding target variables
(δPAMP and δPCWMP), not all the changes from the different portions of the SCG (i.e.,
DTW distances) are relevant to the changes in the mean pressures (MP). For that reason,
we have performed a feature selection technique using sequential forward selection (SFS)
[139]. We selected the top 5 features as the estimating variables in the regression model.
We used LOSO cross-validation for n subjects. At each fold we trained a Ridge re-
gressor on the selected (using SFS method) DTW distances from n-1 subjects, leaving one
subject out. We then predicted the target variables (δPAMP and δPCWMP) for the left-
out subject, repeating this n-1 more times with a different subject excluded each time. As
a result, we obtained predictions for all subjects. We calculated a root mean squared er-
ror (RMSE) between the estimated target variable (δMPPred) and the ground truth target






(δMP Pred(i) − δMPAct(i))2 (6.4)
where n is the number of subjects. We also performed a simple correlation analysis
and Bland-Altman analysis between the true values and the cross-validated predictions of
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δMP across all subjects. We have performed the Pearson correlation analysis between the
estimated and true δMP to get the statistical significance of prediction and calculated R2
between the true and predicted values. In this work, we considered p-values below 0.05 to
be statistically significant.
6.4 Results & Discussion
6.4.1 Effects of Vasodilator on RHCP and SCG
Fig. 6.3 shows the changes in PAP and PCWP signals and the changes in SCGDV with
vasodilator infusion. One thing to note here is that all the signals shown in the figure are
synchronized with the corresponding R-peak. We can see how the overall mean of the PAP
and PCWP signals are decreased with vasodilator infusion, whereas the systolic portion of
the SCGDV signal is right-shifted with vasodilator. With vasodilator infusion, the PAMP
and PCWMP decrease as well as the preload of the heart (the filling pressure of the heart),
and PEP is inversely correlated with preload [32]. For that reason, with a decrease in
preload, we are observing an increase in PEP, which is as expected. The diastolic portion
of the SCG signal is also changing in morphology; however, the change is not very apparent
compared to the systolic portion of the SCG. From this figure, it is apparent that the changes
in SCG signals (specifically in the systolic portion of the signal) with vasodilators have the
potential to track the changes in PAMP and PCWMP.
6.4.2 Feature Correlation
Fig. 6.4 shows the R2 values between the DTW distances from different portions and axes
of the SCG signals with δPAMP and δPCWMP. In the case of δPAMP, the changes in
SCG during the early systole (IVC period) provide the most relevant information related to
changes in the PAMP, with changes in SCGDV during the IVC period showing the highest
R2 of 0.8 with δPAMP. In the case of δPCWMP, the changes in the SCG during the late
diastole (atrial systole) phase provided the most relevant information related to changes
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Figure 6.3: Changes in (a) pulmonary artery pressure (PAP), (b) pulmonary capillary wedge
pressure (PCWP), and SCGDV with the infusion of vasodilator for a representative subject,
with brown arrows showing the changes in the respective signals. Time “0” indicates the
location of the corresponding ECG R-peak.
in PCWMP, with changes in SCGMag during the late diastole period showing the highest
R2 of 0.86 with δPCWMP. Overall, the figure is showing that δPAMP is more related to
the changes in the systolic portion (IVC more specifically) of the SCG signal, whereas
δPCWMP is more related to the changes in the late ventricular diastole (i.e., atrial systole)
portion of the SCG. It might be explained with physiological rationale, as the pulmonary
artery is directly connected to the right ventricle, the ventricular systole (contraction) phase
is dominating the changes in PAMP. On the other hand, the pulmonary capillaries are con-
nected to the left atrium and showing more relation with atrial systole. These preliminary
results should be verified with simultaneous imaging modalities, in a large population study
89
with diversified subjects with various cardiovascular conditions.
Figure 6.4: Correlation analysis of the target variable (a) δPAMP and (b) δPCWMP with
different DTW distances of corresponding SCG signals, with the colorbar showing the R2
values and the red dotted line indicating the division between ventricular diastole and sys-
tole (i.e., R-peak of corresponding ECG). Total Diastole (-500ms:R-peak), early diastole
(-500ms:-200 ms), late diastole (-200ms:R-peak), total systole (R-peak:500ms), early sys-
tole (25ms:150ms), and late systole (200ms:500ms).
6.4.3 Regression Estimation
Fig 6.5 shows the correlation analysis and Bland-Altman analysis between the actual (mea-
sured) and the estimated δPAMP and δPCWMP values, using the selected five DTW dis-
tances with the labels shown in Fig 6.6. The correlation shows a good estimation accuracy
for both δPAMP and δPCWMP, with RMSE of 2.6 mmHg and an R2 of 0.77 for δPAMP,
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and RMSE of 2.2 mmHg and an R2 of 0.88 for δPCWMP. The Bland-Altman analysis
also shows that the regression model was able to predict very high to a very low value
of changes well with a 95% error of estimation within ±5.2 mmHg for δPAMP and ±4.4
mmHg for δPCWMP. The results are showing that the changes in SCG can be used to track
the changes in PAMP and PCWMP. However, this is a pilot study, and the results from this
initial study should be verified with a large population in a longitudinal study.
Figure 6.5: (a) Correlation analysis for δPAMP predicted vs. δPAMP actual, (b) Bland-
Altman analysis for δPAMP predicted and δPAMP actual, (c) correlation analysis for
δPCWMP predicted vs. δPCWMP actual, and (d) Bland-Altman analysis for δPCWMP
predicted and δPCWMP actual. In the Bland-Altman plots, the black line indicates the
mean, while the blue dashed lines indicate mean ± 1.96× standard deviation (SD)
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6.4.4 Feature Importance
Fig. 6.6 shows the relative weights of the features in the Ridge regression for the estimation
of δPAMP and δPCWMP, with the top feature related to δPAMP being the change SCGDV
during the IVC period and the top feature related to δPCWMP being the change SCGMag
during the atrial systole period. Similar to the results obtained from the individual correla-
tion analysis (in Fig. 6.4) between the target variables with the DTW distances, all the top 5
features for the δPAMP are from the systolic portion of the SCG. In the case of δPCWMP,
three of the top five are from the diastolic portion of the SCG and two are from the systolic
portion of the SCG. Both Fig. 6.4 and Fig. 6.6 are showing the importance of the diastolic
portion of the SCG in estimating δPCWMP. Most of the SCG researches are concentrated
on the systolic portion of the signal [39, 58]. Our results suggest that diastolic portion of
the SCG signal also has the potential to provide relevant information regarding pulmonary
congestion.
Figure 6.6: Relative feature importance ranking (i.e., relative weights) of the features in
the regression algorithm for (a) δPAMP and (b) δPCWMP. Dias: Total Diastole, ED: Early
Diastole, LD: Late Diastole, Sys: Systole, ES: Early Systole, and LS: Late Systole. Time-
length for the segments is explained in Fig. 6.4
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6.5 Conclusion and Future Work
In this work, we have estimated the changes in pulmonary artery mean pressure and pul-
monary capillary wedge mean pressure in patients with HF due to vasodilator infusion with
the changes in simultaneously recorded SCG signal. We have developed a global regression
model for the estimation of δPAMP and δPCWMP using state-of-the-art machine learning
algorithms validated with leave-one-subject-out cross-validation. We have demonstrated
that tracking changes in SCG can track changes in the pulmonary congestion (the filling
pressure of the heart), which has the potential to be used for remote home management for
patients with HF. Overall, this work demonstrates the capability of an unobtrusive wearable
patch to track pulmonary congestion. Success in this regard represents a considerable step
towards the hemodynamically-guided affordable HF management for the mass population
affected by HF.
Though this preliminary study has shown good promise in tracking changes in PAMP
and PCWMP in patients with HF, it has multiple limitations. This preliminary study was
conducted with 19 persons only, including both patients with HFrEF and HFpEF. However,
the pathophysiology of the two HF subgroups may present different relationships between
the changes in SCG with changes in PAMP and PCWMP. Due to the small number of sub-
jects for this preliminary study, we could not analyze the difference. Future studies should
verify the analysis of this preliminary study in a large patient population with HF, with
emphasis on the difference between the HF subgroups. We have estimated the changes in
PAMP and PCWMP only. Future studies should look into changes in other key variables
from RHC procedure, e.g., right atrium pressure, right ventricle pressure, stroke volume,
cardiac output, and cardiac index. In this study, we have considered the change in pul-
monary congestion with vasodilator infusion only. Future study should include other phar-
macological agents, e.g., diuretics, beta-blocker, ace-inhibitors, and verify whether changes
in SCG can be used to track changes due to other pharmacological agents as well. We have
93
collected data during the RHC procedure in a controlled clinical environment for acute
changes in pulmonary congestion. To be a reliable sensor for outpatient HF management,
the device and the methods need to be verified with a longitudinal remote home pulmonary
congestion monitoring systems (e.g., CardioMEMS and ReDS). Future studies should also
focus on how the motion artifacts and home data quality may impact estimation accuracy.
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CHAPTER 7
CONCLUSIONS AND FUTURE WORK
7.1 Conclusions of the Presented Work
Recent work on digital health technologies shows promise in transforming HF management
by taking proactive measures based on the sensing of hemodynamic congestion. These new
technologies have improved the individuals’ quality of life and reduced overall health care
cost by improving the worsening symptoms and decreasing readmission. However, the
cost-prohibitive nature of these digital technologies precludes their usage in the large pa-
tient population affected by HF, both in the US and around the world. To overcome this
limitation and to make these technologies broadly accessible, the work presented in this
dissertation aims to pave the way toward an inexpensive, wearable cardiovascular hemo-
dynamic monitoring system that can provide reliable information to clinicians to remotely
monitor the patient population in a hemodynamically-guided HF management system.
We began this dissertation by comparing different wearable sensing modalities to track
changes in cardiac contractility via estimation of PEP, during baseline and exercise recov-
ery in a healthy population dataset. For the first time, we have presented that a gyroscope-
based SCG sensor provided more relevant information regarding PEP compared to an
accelerometer-based SCG sensor. We further presented our argument on the difficulty of
using these biomedical signals in a population-level model due to the inter-subject variabil-
ity of these signals and how extracting general time, frequency, and amplitude features and
developing advanced machine learning regression models to estimate relevant and reliable
hemodynamic features can be used to overcome these difficulties.
We further validated our custom-built wearable patch to record cardioelectromechan-
ical signals (ECG and SCG) and signal processing and machine learning technologies in
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patients with HF during two clinical gold-standard procedures, which showcases the po-
tential of using this sensing modalities and data analysis algorithm in helping a real-world
patient population. For the first validation, we have validated our sensor and analysis algo-
rithm during the CPX test in patients with HF, which is a gold-standard clinical procedure
to stratify risks associated with HF and facilitate advanced heart therapy recommendations.
Our method was accurate in estimating instantaneous VO2 throughout these procedures and
in predicting the outcome of the CPX test in a separate independent validation set, using
the wearable signals alone. Doing so has opened up newer possibilities in longitudinal
monitoring of cardiopulmonary health in patients with HF in their everyday life conditions
during exercise and daily activities. We further translated these methodologies in track-
ing VO2 in a minimally controlled walking activity, in a healthy population dataset, which
showcases the promise of this methodology in cardiopulmonary health monitoring for both
healthy individuals and patients with HF.
For the second validation study, we have validated our sensor and analysis algorithm
in tracking changes in pulmonary artery pressure and pulmonary capillary wedge pres-
sure during the RHC procedure, which is a gold-standard clinical procedure to moni-
tor pulmonary congestion and increased filling pressure of the heart in patients with HF.
Tracking changes in congestion (via tracking pulmonary artery pressure and lung fluid
content) has already shown efficacy in reducing rehospitalization in patients with HF in
hemodynamically-guided treatment methods using CardioMEMS and ReDS system. Our
result of reliably tracking the changes in pulmonary congestion (via tracking changes in
PAMP and PCWMP) has shown the efficacy of this noninvasive low-cost wearable sen-
sor to monitor the pulmonary congestion in patients with HF in a clinical setting and has
opened the possibility of similar tracking in an outpatient HF management. The possible
outpatient HF management can track the worsening HF condition and help the clinicians to
take proactive measures in remote HF management with the help of the SCG-based sensors.
With all three major contributions of this work, we establish the possibilities of us-
96
ing SCG-based wearable sensing, signal processing, and machine learning algorithms to
monitor patients with HF during exercise and daily-life environments. The methodologies
presented here have the potential to yield an accessible and affordable HF management
system that the clinicians and caregivers can leverage for this large patient population.
7.2 Future Directions
Various potential future endeavors can stem from the research presented here. All three
major works presented here were carried out mainly in a controlled laboratory or clini-
cal environment, and a follow-up study was carried out in a minimally controlled outdoor
setting. Future work should take these initial findings to test them in more everyday life
scenarios to quantify if the wearable sensing system and analysis algorithm can be used in
monitoring cardiovascular and pulmonary health in daily living activities (e.g., household
chores, different forms of activities and exercises, etc.), where signal quality and both inter-
and intra-subject variability may pose challenges in using these signals to extract relevant
information from them. This is a necessary step towards true ubiquitous remote home mon-
itoring of the patients with HF. Additionally, most of the patients with HF in this work were
HFrEF. Future work should include more patients with HFpEF, cardiomyopathy, and other
CVDs to analyze how this sensing system and the presented models can generalize in a
diversified data set. Moreover, we have mostly focused on remote monitoring in this work.
The work also has potential application in inpatient decision making using these wearable
sensing modalities. Future work should investigate incorporating these sensing modali-
ties in an intensive care unit (ICU), for inpatient management, and for disease progression
monitoring.
The models and algorithms developed in this works were accurate in tracking changes
in cardiac contractility, oxygen uptake, and changes in pulmonary congestion. Similar
models and algorithm can be extended, perhaps through adding other sensing modalities,
into estimating other key hemodynamic parameters, such as LVET, SV, CO, VE, VCO2,
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pressures in other intra-cardiac and pulmonary chambers.
Though we have shown the accuracy of these sensing systems and advanced machine
learning algorithms in monitoring hemodynamics with patients with HF and healthy sub-
jects only, we can translate a similar approach to extract relevant information for patients
with other chronic conditions, such as tracking cardiotoxicity due to cancer treatments in
cancer survivors and cancer patients undergoing treatments, tracking cardiovascular health
with neurological conditions. Lastly, though these sensing modalities have been researched
and explored for decades, much is still unknown about the origin and pathophysiologically
driven variations of these signals. Future work should investigate inter-subject variability
and effects of different underlying cardiovascular and respiratory conditions on these sig-
nals in a mathematical framework or through finite element method modeling to understand
the changes in the SCG signals we would expect from person to person due to difference
in BMI, gender, and underlying disease conditions. This can, in turn, help us to use this
sensing modality in a population-level model for the large number of patient populations
affected by CVDs and other chronic health conditions.
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